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Abstract
THE ROLE OF NICOTINIC ACETYLCHOLINE RECEPTORS IN ETHANOL
RESPONSIVE BEHAVIORS AND DRINKING
By Anton Jerome Dawson, B.S., B.A.
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2013
Major Director: M. Imad Damaj, PhD
Professor, Department of Pharmacology & Toxicology
The high co-morbidity between alcohol (ethanol) and nicotine abuse suggests
that nicotinic acetylcholine receptors (nAChRs), which are thought to underlie nicotine
dependence, may also be involved in alcohol dependence. A genomic region that
encodes the α5* nAChR subtype has recently been shown to be associated with alcohol
dependence phenotypes in humans. Therefore, the aim of this study was to determine
the role of α5* nAChRs in ethanol-responsive behaviors upon acute administration in
mice as well as in their drinking behavior. We conducted tests in mice lacking the
α5 coding gene (Chrna5) in ethanol-induced hypothermia, hypnosis, anxiolysis, and
conditioned place preference. We also assessed drinking behavior in these mice using
models of voluntary ethanol consumption, two-bottle choice preference and intermittent
access, as well as acute binge drinking behavior in the Drinking-in-the-Dark paradigm.

xii

Our results showed that deletion of the α5* gene enhanced acute behaviors, including
ethanol-induced hypothermia, hypnosis recovery time, and the anxiolytic-like response
in mice. We also found that α5 gene deletion resulted in decreased ethanol CPP, but
had no effect on ethanol consumption in either model of drinking behavior tested under
normal conditions. However, we discovered that under conditions of stress from
multiple daily injections of saline or nicotine, Drinking-in-the-Dark intake was reduced in
α5 null mutant mice. We also examined the role of β2* nAChRs due to the tendency of
the α5 subunit to be co-expressed with this subtype, which also plays an important role
in nicotine dependence. Our results showed that pharmacological and genetic
manipulation of β2* nAChRs modulated some acute alcohol-responsive behaviors,
namely, hypnosis, recovery-time and the anxiolytic-like response produced by ethanol,
but did not modulate ethanol drinking behavior in mice. These studies provide evidence
that α5* subtypes and β2* subtypes, which play a critical role in nicotine dependence,
also play a role in acute ethanol-responsive behaviors in vivo, thus supporting studies in
humans that nicotine and alcohol dependence share common genetic components.

CHAPTER 1: GENERAL INTRODUCTION

1.1

Background and Significance
Alcohol (ethanol) abuse is one of the leading causes of preventable death in society

responsible for nearly 3.2% of deaths worldwide (WHO, 2004). It occurs regardless of
social or ethnic affiliation. It is estimated that at least one person in every family in Western
society has suffered, directly or indirectly, from alcoholism. In the United States alone, 4%
of the population is affected with the estimated economic burden exceeding $366 billion a
year (Chatterjee et al. 2010). Alcohol abuse has vast health consequences contributing to
a multitude of medical complications including damage to several important organs such as
the liver, pancreas, and brain, as well as immune functions. For example, data show that
smoking and alcohol drinking may lead to synergistic increase in risks of various cancers
such as those of the head, neck, esophagus, and duodenum (Meyerhoff et al. 2006).
Alcohol-induced brain damage is a particularly serious problem during pregnancy and
adolescence due to the sensitivity of the developing brain to alcohol. Up to 7/1,000 infants
are born with fetal alcohol syndrome, one of the most common non-genetic, forms of
mental disability (Niccols, 2007). Adolescents, who display as much as a 30% prevalence
rate of binge drinking, have higher sensitivities to alcohol-induced brain dysfunction and
cognitive impairment of the adult brain, and the onset of adolescent drinking increases the
risk for developing alcoholism in the future (Grant & Dawson, 1998; Crews et al. 2000,
Slawecki et al. 2004, Spear et al. 2005). Furthermore, alcohol abuse also has a high
1

comorbidity with psychiatric disorders as well as other addictive behaviors, including
nicotine dependence (Kessler et al. 1994, Swendsen et al. 1998, Funk et al. 2006).
There are few FDA approved medications for the treatment of Alcohol Use
Disorders (AUDs), which currently are limited to disulfiram (Antabuse®), naltrexone
(ReVia®, Depade®, Vivitrol®), and acomprosate (Campral®). Moreover, these drugs have
only managed up to a 30% success rate (Spanagel et al. 2009, Chatterjee et al .2010).
Thus, there remains a clear need for further effective pharmacotherapies in dealing with
these disorders.

While previous treatments have targeted many of the brain

neurotransmitter and neural systems classically associated with alcohol’s effects including
GABA, glutamate, and opioid systems, nicotinic acetylcholine receptors (nAChRs) are
emerging as a likely candidate for the development of novel treatments. Indeed, evidence
suggests that as many as 80% of alcoholics are smokers and the high incidence of
smoking and alcohol co-abuse that nAChRs play an important role in alcohol consumption
and relapse-like behavior (Istvan et al.1984, Falk et al. 2006, Pothoff et al. 1983, Blomqvist
et al. 1996, Lé et al. 1996). Furthermore, there is evidence showing that genetic factors
are predictors of both long-term alcohol and tobacco consumption (see Schlaepfer et al.
2008 for review). Because of the estimation that common genetic factors account for as
much as 40% of the covariance between alcohol and nicotine abuse (Swan et al. 1997), it
is very likely that such genetic factors (i.e. nAChRs) underlying smoking addiction are
common to those underlying AUDs as well. This notion is supported by clinical evidence
showing that drugs targeting nAChRs such as the nonselective antagonist mecamylamine
and the partial agonist and smoking cessation aid varenicline (ChantixTM) actually reduce
alcohol consumption in human subjects (Chi et al. 2003, McKee et al. 2009).
2

The goal of this thesis is to use animal models to explore the role nAChRs play in
important pharmacological and behavioral responses to alcohol in the hope of
contributing new findings that could lead to the discovery of novel therapeutic targets
that may aid in curbing excessive alcohol drinking and, potentially, smoking addiction
simultaneously. The following section of the introduction will discuss the structure and
function of nAChRs as well as review the relevancy of these receptors to AUDs as
discovered by human and animal studies. The next section will provide an overview of
the molecular mechanisms by which AUDs are thought to arise. The chapter will then
be concluded by reviewing the current evidence suggesting nAChRs as genetic
elements in mediating alcohol’s behavioral effects.

1.2

Structure and Function of Nicotinic Acetylcholine Receptors
Nicotinic Acetylcholine Receptors are part of the superfamily of ligand-gated ion

channels. They have a shared common basic structure that is permeable to mono- and
divalent ions under control of extracellular signaling molecules (see Hurst et al. 2013 for
review). These receptors have been conserved throughout evolution, with human
nAChRs sharing a high degree of structural homology with many organisms, from
animals all the way down to the simplest forms of life, such as some bacteria (Thany et
al. 2007). These structures are divided into distinctive subtypes, each retaining specific
functions and capable of mediating unique pharmacological effects. To date, 16 genes
have been indentified in mammalian genomes that code for distinct nAChR subunits
that comprise each receptor subtype found in the body (Dani & Bertrand, 2007; Lukas et
al. 1999). While it is true these genes code for nAChRs found in both the central and
3

peripheral nervous systems, this review will focus specifically on those that code for
receptors in the brain (neuronal nAChRs). Each neuronal nAChR subtype consists of
five subunits comprised of α(α2−α10) and/or β(β2−β4) subunits that form around a
central pore (Figure 1A). Each subunit contains a hydrophilic extracelluar amino
terminal that faces the synaptic cleft, followed by three hydrophobic transmembrane
domains (M1-M3), a large intracellular loop, and a forth hydrophobic (M4)
transmembrane domain (Figure 1B). These domains are precisely arranged to facilitate
the passage of cations such as Na+, K+, and Ca2+ through the pore following the binding
of an extracellular signaling molecule to the ligand binding domain (LBD). The pinwheel
structure forms the five subunit complex consisting of a primary face carrying
α2, α3,α4,α6, α7, α8, and/or α9 subunits, and a complementary face carrying
β2, β4, α7, α8, α9 and/or α10 subunits (Elgoyhen et al. 2001). Each receptor subtype
exists as a heteromeric (α2−α6,α10 and β2−β4, Figure 1C) or homomeric (α7, α8, and
α9, Figure 1D) structure containing either two or five binding sites, respectively.
The nicotinic receptor exists in three general states, namely, resting (closed),
open, and desensitized at any given moment (Figure 2). When stimulated by agonist
binding to the orthosteric site, nAChRs transition from the closed to open state, allowing
an influx of cations and thus depolarizing the cell membrane and increasing neuronal
excitability. The influx of the cations, particularly Ca2+, leads to changes in a wide array
of intracellular signaling cascades. The transition rate of each state is influenced by the
binding of endogenous and/or exogenous extracellular ligands, not only at the LBD, but
also at allosteric sites on the receptor. Following activation, the receptor will either
return to the resting state upon agonist dissociation (deactivation), or transition into a
4

high affinity, agonist-bound, non-conducting state known as desensitization. The
frequency and length of this transition state depends on a variety of parameters, and
subunit composition differentially contributes to the rate and probability of
desensitization (Giniatullin et al. 2005, Quick & Lester 2002). Virtually all nAChRs
display low affinity for natural agonist and fast transition from the resting to open state;
two critical properties for the fast, high frequency signaling that occurs at synapses.
Nicotinic receptors in the mammalian brain are primarily expressed at
presynpatic, peri-synaptic, and extra-synaptic sites where their most common role is to
modulate neurotransmitter release (Hurst et al.2013). This is a principal reason why
nAChRs are theorized to play a critical role in drug dependence since they modulate the
release of several other neurotransmitters associated with drug dependence.
Receptor distribution is another key factor that determines the neurobiological effects
mediated by nAChRs. Various approaches are used to indentify nAChR distribution.
These include mRNA expression analysis of different brain regions using specific
primers, employing radiolabeled nicotinic ligands with sufficient selectivity and sensitivity
for targeted subtypes, using antibodies as specific markers for nAChR subunit proteins,
and examining the functional and pharmacological sensitivity of receptors expressed in
various brain areas (Hurst et al. 2013).
It should be noted that the stoichiometry of a particular nAChR also affects the
interaction with its respective ligand. For example, α4β2* nAChRs, which are highly
sensitive to ACh and nicotine, have differing affinities based on the number of α and
β subunits. Those with a greater number of β subunits, (i.e.(α4)2(β2)3 nAChRs), have

5

nearly 100 times greater affinity for its agonist than those with less,(i.e (α4)3(β2)2
nAChRs) (Carbone et al. 2009, Zwart et al. 1998, Nelson et al. 2003).
Many nAChR subtypes are found in brain regions relevant to drugs of abuse
such as the ventral mesolimbic pathway, dorsal nigrostriatal pathway, and hanbenulointerpeduncluar pathways (Koob & Volkow, 2010). The α7 and α4β2* nAChRs are
expressed ubiquitously throughout the brain, the latter comprising up to 90% percent of
high affinity nAChR expression in the mammalian brain (Gotti et al. 2004, Albuquerque
et al. 2009). α4β2* nAChRs are also among the principle contributors to nicotine
addiction given their critical role in the rewarding and reinforcing properties of nicotine,
while α7 is known to contribute to nicotine’s withdrawal effects (see de Biasi & Salas,
2008 for review). However, there are other noteworthy subtypes relevant to drug
addiction with more discrete distribution in the brain, among them α3*, α5*, and α6*
nAChRs (Figure 3, also see Gotti et al. 2009 for review). The α3* nAChR subtype is
found to be expressed in high levels in the pineal gland, medial habenula (MHb),
hippocampus, interpeduncular nucleus (IPN), and dorsal medulla existing as α3β4*
nAChRs, which acts primarily in conducting fast synaptic transmission (Schlaepfer et al.
2008a). Additionally, α3* nAChRs are found in the retinal visual pathways expressed
mainly as α3β2*, which can also be found in the MHb (Gotti et al. 2007, Grady et al.
2009). Next are α5* nAChRs, which, much like α3β4*, are expressed in the pineal
gland, MHb, IPN and dorsal medulla, as well as in the ventral tegmental area (VTA) and
the prefrontal cortex where high densities of α4β2* exist (Schleapfer et al. 2008a). This
is not by chance, as the α5 subunit must co-assemble with either of the aforementioned
6

subtypes, as well as α3β2* in other cases, to form a functioning α5* receptor (Kuryatov
et al. 2008). The α5 subunit acts as an “accessory” protein where it influences the
sensitivity, agonist efficacy, Ca2+ permeability, and desensitization properties of its
respective receptor (Gerzanich et al. 1998, Brown et al. 2007, Tapia et al. 2007).
Furthermore, the α5* subtype was shown to be a critical component of α-Conotoxin MIIresistant dopamine (DA) release in the mesolimbic dopamine system (MDS) because
α5 gene deletion resulted in decreased maximal ACh-stimulated dopamine release and
α5* nAChRs were found to be expressed in striatal synaptosomes in the mouse (Grady
et al. 2010, Brown et al. 2007). Deletion of the α5 gene also reduced GABA release in
mouse striatal synaptosomes, thus demonstrating the important functional implications
α5* nAChRs have not only on DA-mediated reward mechanisms, but also on the
release of other neurotransmitters relevant to drug dependence (Grady et al. 2010).
Finally, the α6* nAChR subtype has emerged as another important subtype in
determining the contribution of nAChRs to drug dependence due to its high, virtually
exclusive expression on DA neurons within the substantia nigra, VTA, and locus
coreleus (Yang et al. 2009). It is an especially peculiar subtype given its complexity in
forming fully functional receptors. For instance, functional subtypes cannot be
expressed in vitro without co-expression with α4, β4, or β3 subunits, and no naturally
expressed receptors have not been observed in vivo without the presence of β subunits
(Kuryatov et al. 2000). Immunopurification data shows two major α6* subtypes,
α6α4β2β3* and α6β2β4*, were found in the striatum, retina, and superior colliculus, with
the former comprising up to 60% of all α6* nAChRs (Gotti et al. 2007). Also, the
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presence of the β3, which is also an accessory subunit, seems to be important since
deletion of the β3 gene dramatically reduces α6* expression (Gotti et al. 2005).
Evidence shows that the majority of α6* nAChRs in the striatum are expressed on
presynpatic DA neuron terminals and are important for mediating DA release in this
brain region, thus underscoring their potentially critical role in drug dependence
(Salminen et al. 2004). While the majority of the preceding descriptions mainly refer to
expression patterns in rodents, data suggests that these do not differ greatly from
primates (Gotti et al. 2006a). In conclusion, much remains to be discovered about
nAChRs, but given their complexity and ubiquitous expression throughout the brain and
body, it is no wonder why they remain a focal point in the search for molecular targets
for the development of more effective pharmacotherapies for drug dependence.

8

Changeux et al. 2010
Figure 1. Neuronal nicotinic acetylcholine receptor structure. (A) Each subtype consist of five
subunits comprised of α(α2−α10) and/or β(β2−β4) subunits that form around a central pore, which
are permeable to Na+ and Ca2+ cations. (B) Each subunit contains a hydrophilic extracelluar
amino terminal facing the synaptic cleft followed by three hydrophobic transmembrane domains
(M1-M3), a large intracellular loop, and a forth hydrophobic (M4) transmembrane domain.
Receptor subtypes exist as (C) heteromeric pentamers containing α2−α6,α10 and β2−β4 or (D)
homomeric pentamers comprised of α7, α8, or α9 subunits. Each structure contains either two or
five ACh binding sites, respectively.
9

Hurst et al. 2013

Figure 2. Functional states of neuronal nicotinic acetylcholine receptors. The binding of two
agonist molecules (five for homopentamers) causes a transition from the closed state, to the open
state, which allows cation influx through the channel pore. Following activation, the receptor will
either remain in an agonist-bound, non-conducting state (desensitization) or return to the resting
state upon agonist dissociation (deactivation).
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FIgure 3. Distribution of neuronal nicotinic acetylcholine receptors in the rat brain
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1.3

Molecular mechanisms involved in Alcohol Dependence
In light of the complexities associated with determining the underlying causes of

alcohol addiction, great strides have been made in the last 20 years in advancing our
knowledge of alcohol pharmacology (see Spanagel et al. 2009 for review). Although,
historically, alcohol was thought to be a relatively unspecific pharmacological agent,
intense study over the past two decades reveals that this drug has at least a few known
primary targets that mediate its more significant effects on brain signaling. While it is
true that alcohol can exert a number of significant effects via its metabolic products (i.e.
acetylaldehyde), the typical acute behavioral effects associated with acute alcohol
exposure are primarily attributed to the first direct hit of ethanol on specific molecular
targets followed by numerous indirect effects on a variety of neurotransmitter/peptide
systems (Vengeliene et al. 2008, Spanagel et al. 2009). These effects, in turn, result in
alterations in gene expression, leading to lasting neurophysiological changes that can
trigger alcohol-seeking behavior with repeated exposure. Eventually, such changes
may result in addictive behavior depending on genetic makeup of the individual as well
as many environmental factors. While it was a long previously held view that ethanol
mediates its action by membrane disruption (lipid theory), evidence has shifted from this
view to one that asserts that ethanol has primary targets (protein theory). Among these
, ligand-gated ion channels including glutamate (NMDA), GABAA, glycine, 5-HT3 and
nACh receptors, though many other notable molecular targets also exist. Studies show
that each of these receptor types are differentially affected in a wide range of blood
ethanol concentrations (BECs) from those that cause mild behavioral intoxication (~1020 mM) to loss of consciousness (> 300 mM). Generally, the degree of modulation is
12

directed by the receptor class and subtype. In a concentration range sufficient to
produce intoxication, ethanol generally inhibits NMDA receptors and L-Type Ca2+
channels, while potentiating GABAA, glycine, 5-HT3, and nACh receptors (Lovinger et al.
1989, 1991; Mihic et al. 1997, , Narahasi et al. 1999). Additionally, the sensitivity of
each receptor type to ethanol depends on both subunit composition and ethanol
concentration. For example, most GABAA receptors are sensitive to ethanol
concentrations >60 mM, but those containing a δ subunit can be activated at
concentrations as low as 1-3 mM (Wallner et al. 2003). Furthermore, α4/α6β3*
subtypes are 10 times more sensitive than β2* subtypes (Wallner et al. 2003). In
glycine receptors, α1* subtypes appear more sensitive to low concentrations of ethanol
than α2* (Mihic et al. 1997). In nAChRs, α2β4, α4β4, α2β2, and α4β2 (but not α3β2 or
α3β4) subtypes are potentiated by ethanol concentrations <100 mM, while the α7
subtype is inhibited up to this concentration (Harris et al. 1999). The differential
distribution of all of these receptors and their respective subtypes will affect some brain
regions more than others, which ultimately dictate the net effect ethanol will have on
brain signaling and behavior.
The actions of ethanol directly on the aforementioned ion channels, in turn,
causes a multitude of indirect effects on a wide array of neurotransmitter/peptide
systems crucial for the initiation of drinking behavior (Vengeliene et al. 2008). Among
these, alteration of signaling involving monoamines, opioiods, and endocannabinoids,
seem to have the greatest effect on reward and reinforcement necessary for the
acquisition of alcohol drinking. The mesolimbic dopamine system (MDS), in particular,
has been characterized as a neurochemical substrate for drug reinforcement, with A10
13

dopamine neurons identified as a critical component of this event (Schultz, 2007; Wise
et al. 1989, 2004). A myriad of animals studies strongly support a significant effect of
ethanol on the MDS. Though the details of these studies extend past the scope of this
thesis, summarily, systemic ethanol mediates its action via neurochemical access points
(i.e. GABAA, 5-HT3, glycine and nAChR receptors), which affects dopamine
transmission in the nucleus accumbens (NAC), VTA, and its afferents, thus influencing
the A10 DA neurons essential to primary alcohol reinforcement processes. In addition
to the DA-mediated processes previously mentioned, ethanol triggers the release of
numerous endocannabinoids and opioiods, which have been shown to be vital in
ethanol’s rewarding effects. Furthermore, the mechanisms through which these actions
are mediated appear by processes both dependent and independent of the MDS (Koob
& Volkow et al. 2010)
The complexities of all these interactions are compounded by the fact that
ethanol causes both acute and lasting changes in gene expression upon repeated
exposure to the drug. There are many changes in signal transduction caused by
ethanol exposure, but a primary pathway worth highlighting is the cAMP-PKA pathway
that involves the activation of cAMP response binding element (CREB). This
transcription factor leads to the expression of numerous ethanol-responsive genes
(Diamond et al. 1997, Ron et al. 2005). These genes control significant physiological
functions including neurotransmission, cell structure, signal transduction, metabolism
and more (Lonze & Ginty, 2002). Among these CREB-targeted genes, some of the
most notable regarding alcohol dependence include corticotropin releasing factor
(CRF), prodynorphin, brain-derived neurotrophic factor, and neuropeptide Y, though
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there are numerous others (Heilig & Koob 2007, Blednov et al. 2006, Martinez et al.
2005, Thiele et al. 1998, Crabbe et al. 2006a). Additionally, there are also CREBindependent genes as well as epigenetic effects induced by ethanol (Aragon et al. 1991,
Egger et al. 2004, Saxonov et al. 2006). All these aforementioned changes may occur
in a regionally-specific manner or in the brain as a whole. Thus, while the complexities
of ethanol’s actions on the brain are vast, they also present many opportunities in the
way of these molecular targets for discovering more effective treatments for AUDs.
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1.4 Nicotinic receptor mechanisms Involved in Alcohol Dependence
1.4.1. Human behavioral and genetic data
Several studies present evidence for nAChRs as potential candidates for
mediating phenotypes that characterize alcoholism. The high comorbidity of nicotine
and alcohol abuse seem to implicate these receptors in phenotypes related to
alcoholism especially due to the knowledge that nAChRs are the principle contributors
to the addiction relevant actions of nicotine (Kenny et al. 2001, Tuesta et al. 2011). It is
estimated that up to 45% of alcoholics display nicotine dependence compared to 13% in
the general population, and likewise, 13% of nicotine dependent individuals display
alcoholism compared to 4% in the general population (Romberger & Grant, 2004;
Grucza et al. 2006). Furthermore, not only is chronic smoking in alcoholic individuals
associated with higher levels of alcohol consumption compared with nonsmoking or
former smoking alcoholics, but alcoholic individuals actually seem to display more
severe forms of nicotine dependence than that of non-alcoholic smokers (York & Hirsch,
1985; Romberger & Grant, 2004). While it can be argued that co-abuse of these
substances is attributable to the easy availability and low social stigma of cigarettes and
alcohol, neurobiological evidence suggest a much deeper connection such conditions
alone do not fully explain (Feduccia et al. 2012, de Fiebre et al. 1990, Smith et al. 1999,
Gould et al. 2001, Marubio et al. 2003, Tizabi et al. 2007). This may be the reason why
tobacco is among the most commonly abused substances by actively drinking and
recovering alcoholics. However, this clear correlation between alcohol and nicotine
abuse presents an opportunity in that it makes nAChRs an attractive target for the
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treatment of both AUDs and possibly nicotine dependence simultaneously (Chatterjee
et al. 2010).
Indeed, preliminary behavioral evidence in the way of this notion has already
been demonstrated in humans during clinical trials. For example, mecamylamine, a
non-specific nAChR antagonist, appeared to suppress the stimulant effects of alcohol
as well as the desire to consume more alcohol in healthy volunteers with no history of
substance abuse in several independent studies (Blomqvist et al. 2002, Chi et al. 2003,
Young et al. 2005). Similarly, varenicline, a non selective α4β2* nAChR partial agonist
approved as a smoking cessation aid by the FDA, recently showed that it reduced the
rate of drinking in heavy-drinking smokers, as well as their likelihood of remaining
abstinent during the clinical trial (McKee et al. 2009). Conversely, studies have also
shown that some pharmacotherapies that are prescribed for the treatment of AUDs (e.g.
naltrexone) also appear to reduce smoking levels in alcoholic smokers (Rohsenow et
al.2003). Moreover, nAChRs are known to play a vast role in attention processes,
learning and memory, synaptic plasticity, and neuroprotection, all of which are also
affected by alcohol consumption; so it is logical to assume they can act as a common
site of action for the neurocognitive modulations associated with alcohol abuse. For
instance, abstinent alcoholic individuals appear to be more sensitive to nicotine’s
cognitive enhancing effects than substance abuse users without a history of alcohol
dependence (Ceballos et al. 2006). Such evidence provides further support for nAChRs
as potential targets for the treatment of AUDs.
In addition to the behavioral evidence previously described, genome-wide
association (GWA) studies have implicated genes coding for specific nAChR subunits in
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alcohol dependence phenotypes. Among these findings, GWA analyses of a
chromosome region containing the CHRNA5/A3/B4 gene cluster, coding for α5, α3, and
β4 nAChR subunits, respectively, have produced many intriguing results regarding not
only alcohol, but multiple substances of abuse (Lubke et al. 2012 for review). While the
majority of the data generated pertain to smoking dependence, a few independent
studies containing subjects suffering from multiple symptoms of substance abuse also
revealed an association with alcohol phenotypes. For instance, a study of young adults
testing for association of single nucleotide polymorphisms (SNPs) in the
CHRNA5/A3/B4 genomic region with multiple alcohol and nicotine dependence
phenotypes revealed a number of SNPs that were associated with age of initiation of
alcohol drinking (Schlaepfer et al. 2008a,b). These results were replicated in a separate
population-representative adult sample. An independent study corroborated these
results, revealing that many alleles within this same chromosome region showed an
association with alcohol (and cannabis) dependence (Wang et al. 2009). Additionally,
two independent samples derived from a panel of subjects diagnosed with nicotine
dependence and other psychiatric disorders showed a significant association of two
SNPs, rs16969968 and rs1051730, in the CHRNA5/A3/B4 genomic region with DSM-IV
symptom counts for alcohol dependence and the Fagerstrom Test of Nicotine
Dependence (FTND), a common assessment of nicotine dependence. Interestingly, the
alleles associated with alcoholism risk were the opposite of those associated with risk
for nicotine dependence as the alleles associated with risk for alcoholism were the G
variant of each marker, while the A variant of these same markers were associated with
a higher FTND score (Chen et al. 2009). Further analysis using both novel and
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replicated data sets also supported an association of these same two SNPs with alcohol
dependence in subjects diagnosed with multiple substance abuse (Sherva et al. 2010).
Additional SNPs, in the CHRNA5/A3/B4 genomic region were also shown to be
significantly associated with quantitative level of response, specifically body sway
induced by acute alcohol challenge, in normally drinking young adults that were family
history positive for alcoholism (Joslyn et al. 2008). More recent evidence also shows a
SNP in this genomic region, particularly in CHRNA5, showed a significant association
with SHAS, a measure of subjective feelings of intoxication, in a sibling pair study in
which subjects had at least one alcoholic parent (Choquet et al. 2013). Thus evidence
continues to build that suggests at least a modest contribution of the CHRNA5/A3/B4
genomic region to influencing the development of AUDs.
GWA studies searching for additional nAChR gene associations with alcohol
phenotypes revealed that CHRNB2, CHRNA6, and, CHRNB3, coding for the β2, α6, and
β3 nAChR subunits, respectively, were also associated with various traits such as
subjective response to early alcohol exposure and heavy alcohol consumption. More
specifically, analysis of the β2 gene revealed an association of a rare SNP with early
subjective response to alcohol in a study demonstrating that individuals expressing a
variant of the gene recalled a strong negative response to initial episodes of alcohol
(and nicotine) use (Ehringer et al. 2007). As for CHRNA6 and CHRNB3, three SNPs in
the α6 gene and one in the β3 gene showed an association with a handful of
alcoholism-related traits including average number of drinks in individuals from a
nationally representative sample of households (Hoft et al. 2009). Another independent
study identified SNPs associated in the α6 (but not β3) gene with heavy alcohol
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consumption in a Spanish population of heavy drinkers (Landgren et al. 2009). Though
more consistent data have been generated with regard to the CHRNA5/A3/B4 genomic
region, it remains evident that at least some nAChRs appear to be common genetic
elements for influencing risk for alcoholism, at least to some degree.

1.4.2. In vitro and In vivo data
Studies, both in vitro and in vivo, continue to compile evidence for the
involvement of nAChRs in ethanol-responsive behaviors. In vitro studies conducted
since the mid-1980s recognize that nAChR activity is modulated following ethanol
application. This is not surprising considering the structural similarity between these
and GABAA receptors, which are significant targets of ethanol’s neuromodulatory action.
Studies show that the α2β4, α4β4, α4β2, and α2β2 nAChRs subtypes are potentiated,
while α7 nAChRs are inhibited at ethanol concentrations up to 100 mM when expressed
in Xenopus oocytes, as well as in naturally expressed nAChRs in PC-12 cells, mouse
synaptosomes, and cultured cortical neurons, among others (Aistrup et al. 1999,
Narahashi et al. 1999, Harris et al. 1999). Data for α3β4 nAChRs revealed that these
receptors are largely insensitive within this concentration range (Harris et al. 1999,
Aistrup et al. 1999, Cardoso et al. 1999).

However, all nAChRs appear to be

potentiated at ethanol concentrations greater than 100 mM.
There are also numerous in vivo studies demonstrating nAChR involvement in
ethanol’s behavioral effects in animals.

Studies dating back to the late 1980’s

demonstrate the ability of nAChR ligands to alter the effects of ethanol after both acute
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administration and chronic exposure. For example, nicotine and ethanol produce crosstolerance to each other’s effects in a variety of physiological and behavioral measures
including body temperature, heart rate, and hypnosis, as well as in open-field and Ymaze activity (de Fiebre & Collins 1993, Collins et al. 1988, 1996). Additionally, many
nAChRs ligands are shown to alter ethanol’s effects on neurotransmission, suggesting
that nAChRs act a common molecular site of action for these drugs. The most notable
interactions occur within the MDS (see Soderpalm et al. 2009 for review). Studies show
that ethanol indirectly activates this system via central nAChRs by elevating ACh levels
in the ventral tegmental area (VTA), thereby leading to increased DA levels in the NAC
(Ericson et al. 2003, Larsson et al. 2005). Numerous nicotinic receptor ligands alter
changes in DA transmission within the MDS in response to ethanol. For example,
ethanol-induced DA elevation in the NAC is blocked when, mecamylamine, a nonspecific antagonist is infused in the anterior VTA (Blomqvist et al. 2002, Lof et al. 2007a,
Ericson et al. 2008).

Similarly, VTA infusion of α-conotoxin MII (α3β2* and α6*

antagonist) and systemic injection of varenicline (α4β2* partial agonist), also block
ethanol-induced DA elevation in the NAC in rodents (Ericson et al. 2003, 2008, 2009).
In

contrast,

neither

Dihydro-β-Erythroidine

(DHβE,

α4β2*

antagonist)

nor

methyllycaconitine (MLA, α7 antagonist) seem to alter ethanol-induced dopamine
release (Larsson et al. 2002, Ericson et al. 2003).
Given such data, it is not surprising to find that manipulation of nAChRs also alters
acute ethanol-responsive behaviors as well as self-administration behavior in animals.
In line with their observed effects on ethanol-induced DA transmission, mecamylamine
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and α-conotoxin MII infused into the VTA and systemic injection of varenicline (but not
DHβE or MLA) all demonstrate a reduction of ethanol self-administration behavior in
rodents (Ericson et al. 2003, 2008, and 2009, Steensland et al. 2007, Hendrickson et al.
2009, Kamens et al. 2010).
block

acute

Furthermore, mecamylamine and α-conotoxin MII also

ethanol-induced

increase

in

locomotor

activity

and

conditioned

reinforcement of ethanol (Larsson et al. 2002, Jerlhag et al. 2006, Lof et al. 2007b).
Nicotine, which targets multiple nAChRs subtypes, also displayed the ability to modulate
ethanol drinking behavior in multiple self-administration assays in rodents, although
findings have been somewhat conflicting. Some studies report increased ethanol intake
(Clark et al. 2001, Lê et al. 2000, 2003, 2010), while others report a decrease in ethanol
intake (Hendrickson et al. 2009, Sharpe & Sampson 2002) with discrepancies in the
results likely due to the variation in experimental methods including length of exposure
to the drugs, route of administration, and drug concentration among others (Burns &
Proctor, 2013),
While pharmacological antagonism of α4β2* nAChRs by DHβE and α7 nAChRs by
MLA has no effect on ethanol self-administration directly (Lê et al. 2000, Hendrickson et
al. 2009) studies do demonstrate the ability of these nAChRs to alter response to some
effects of acute ethanol administration.

For instance, both DHβE pretreatment and

deletion of the β2 nAChR gene attenuate ethanol-induced loss of righting reflex (LORR),
as well as reduction of the acoustic startle response and increased open arm time in the
elevated plus maze (Owens et al. 2003, Butt et al. 2004, Dawson et al. 2013).
Furthermore, ethanol-induced ataxia was attenuated in mice pretreated with the β2* full
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agonists nicotine and metanicotine (RJR-2403), effects that were blocked by DHβE (AlRejaie et al, 2006 a,b,c; Taslim et al. 2008). The α7 nAChR also seems to influence
ethanol’s acute effects on some level. Deletion of the gene in the mouse resulted in an
enhanced response to ethanol’s effects in open-field activity, hypothermia, and LORR
response, while activation of α7 nAChRs by the agonist PNU-282987 attenuated
ethanol-induced ataxia; an effect blocked the α7 antagonist, MLA (Bowers et al. 2005,
Taslim et al. 2010).

Additionally, α6* nAChRs were also shown to influence the

sedative effects of ethanol as the α6 gene increased sensitivity in the LORR response,
while having no effect on two-bottle choice ethanol consumption (Kamens et al. 2012).
As for ethanol drinking behavior, however, the data suggests that α3β2* and α3β4*
nAChRs appear to be among the likely candidates for influencing ethanol selfadministration directly in rodents of the nAChRs assessed so far.

As previously

mentioned, α-conotoxin MII, which targets α3β2* and α6* nAChRs (Cartier et al.1996,
Champtiaux et al. 2002), was shown to curb ethanol consumption in rodents, but further
studies with α6* ruled out the involvement of this subtype due to the observation that α6
knockout mice drank similarly to wild type (Kamens et al. 2012). Additionally, studies
show that partial agonists targeting α3β4* nAChRs as well as genetic overexpression of
this subtype reduce ethanol consumption in rats and mice, respectively (Chatterjee et
al. 2011, Gallego et al. 2012).

Moreover, cytisine and its derivative, varenicline,

reduced ethanol consumption in rodents in many tests of drinking behavior (Steensland
et al. 2007, Hendrickson et al. 2009, 2010; Kamens et al. 2011, Sajja et al. 2011, 2012).
While both drugs are known primarily as high affinity α4β2* partial agonists, they also
23

act as full agonists of α3β4* nAChRs and display some activity at α3β2* and α7 nAChRs
as well (Papke & Heinemann 1994; Zatónski, 2005, Mihalak et al. 2006).

Finally,

nicotine, which is a full agonist at each of the aforementioned subtypes, has been
shown to modulate ethanol drinking behavior in multiple studies (Clark et al. 2001,
Sharpe & Sampson, 2002; Lê et al. 2000, 2003, 2010; Hendrickson et al. 2009, Burns &
Proctor et al. 2013). Interestingly, the genes that code for these receptor subunits
implicated by these studies were also identified in human GWA studies.
Another nAChR subtype worthy of mention is that which contains the α4 subunit,
although, its involvement in ethanol drinking directly appears more complex.

For

example, the α4β2* antagonist DHβE had no effect on ethanol drinking behavior in
multiple studies (Larsson et al. 2004a,b; Lé et al. 2000, Hendrickson et al. 2009), but
these receptors were shown to be sufficient for nicotine and varenicline-induced
reduction of ethanol consumption in mice (Lé et al. 2000; Hendrickson et al. 2009, 2010,
2011). Furthermore, Leu9’Ala mice that express α4* nAChRs hypersensitive to nicotinic
agonist (Ross et al. 2000, Tapper et al. 2004), showed similar consumption between
nicotine and varenicline test groups, and their respective controls.

Such evidence

supports the idea that α4* nAChRs are important in mediating the effects of these drugs
on ethanol consumption. This may be explained by the inability of ethanol to further
activate DA neurons in the VTA via these nAChRs after agonist (i.e. varenicline,
nicotine) binding. This notion is supported by data showing reduced and enhanced DA
activation by ethanol in α4 KO and Leu9’Ala mice, respectively, which was corroborated
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by respective changes in ethanol CPP behavior, another VTA-dependent mechanism
(Hendrickson et al. 2010, 2011; Liu et al. 2012).
One oversight of increasing significance in the aforementioned in vivo studies,
however, is the α5* nAChR subtype.

While recent data does suggest a potential

genetic correlation between α5 mRNA expression levels and ethanol preference
(Symons et al. 2010), as well as some involvement in ethanol’s acute sedative effects in
mice (Santos et al. 2012), the role of this particular subtype on ethanol-responsive
behaviors in vivo remains largely unexplored. As described previously, the α5 nAChR
gene was identified in numerous GWA studies as having a potential link to several
alcohol dependence-related phenotypes in humans (Joslyn et al. 2008, Schlaepfer et al.
2008a,b; Wang et al. 2009, Chen et al. 2009, Sherva et al. 2010, Choquet et al. 2013).
Moreover, α5* nAChRs play an inexorable role in nAChR agonist-evoked DA
transmission within the MDS (Grady et al. 2010), and this subtype was shown to be
critically important in mediating in vivo self-administration and the rewarding effects of
nicotine in rats and mice (Fowler et al. 2011, Jackson et al. 2010, Tuesta et al. 2011).
Given that nicotine is a drug whose use displays high co-morbidity with alcoholism, a
more detailed in vivo characterization of α5* nAChRs may likely reveal some critical
insights on their role in alcohol dependence as well.

Moreover, the α5 subunit is

commonly co-expressed with both α4β2*, α3β4*, and α3β2* nAChRs (Gerzanich et al.
1998, Wang et al. 1998, Mao et al. 2008) and, thus, may be able to explain the deeper
mechanisms underlying the effects of these receptors on ethanol consumption.
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CHAPTER 2: MODELING ALCOHOL DEPENDENCE

2.1

Modeling Alcohol Dependence in humans
The sheer heterogeneity of AUDs makes alcoholism very difficult to classify and

diagnose. Traditionally, alcoholism is diagnosed according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV), which suggests a list of symptomatic
criteria the alcoholic individual should exhibit. However, these criteria alone often lead
to binary classifications that fail to capture the heterogeneity of AUDs (Hines et al.
2005). Generally speaking, alcohol addiction can be thought of as a clinical outcome
generated by a complex combination of risk factors, believed to be intergenerationally
transmitted via genetic and environmental influences. Nearly 50% of the risk variance
for AUDs is determined by genetic influences (Spanagel et al. 2009). While the
interactions of these genetic components are far too complex for a solitary pathway to
explain the genetic link to behavior, scientists have identified endophenotypes that
continue to provide important information on susceptibility to AUDs (Knopik et al. 2004,
Lyons et al. 2003, Hines et al. 2005). Understanding and modeling specific
endophenotypes associated with AUDs could lead to the identification of underlying
genes that are critical to diagnosing and treating alcoholism.
While there are countless endophenotypes, ranging from comorbid psychiatric
disorders to alcohol metabolic enzymes, five over-arching endophenotypes containing
the majority of the genetically-related alcoholism risk factors have been indentified as
neuronal/behavioral inhibition, major psychiatric disorders, the opioid system, alcohol
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metabolism, and the subjective level of response to alcohol (see Hines et al. 2005 for
review). Of all the endophenotypes mentioned, subjective response (SR) to alcohol
perhaps ranks among the most discussed as of late (see Morean & Corbin, 2010 for
review). Since first being identified in the early 1980s, empirical evidence suggest that
SR accounts for up to 60% of the variance of AUD risk conferred by genetics (Schuckit
et al. 1999). SR, which represents the individual differences in sensitivity to the
pharmacological effects of alcohol, is typically measured by alcohol challenge
paradigms establishing family history or drinker status, then challenging the subject with
enough alcohol to produce a targeted breath or blood alcohol level (BAL). These
measures are then captured using a self-reporting tool (i.e. Subjective High Assessment
Scale, SHAS) to assess the subjective state of the participant. Additionally,
physiological assessments such as static ataxia, body sway, heart rate, and many other
factors are often used in conjunction with these self-reported measures to more clearly
define the level of response in each individual. The two main theoretical views used to
explain SR are the Low Level of Response Model and the Differentiator Model. The
Low Level of Response (LLR) Model contends that a dampened response to alcohol’s
effects confer risk for negative alcohol outcomes, suggesting the possibility that LLR
reflects a faulty feedback mechanism in which individuals fail to adequately regulate a
level of intoxication that normally serves a signal to stop drinking (Schuckit et al. 1994b,
Schuckit & Smith 2000). This, in turn, may lead to increased tolerance over time, which
furthers risk for alcoholism. The most recent and substantial results for LLR have been
produced by ongoing studies performed by Schuckit and colleagues since the 1990s,
though long previous work on this phenomenon do exist (see Pollack, 1992 for review).
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Both non-placebo and placebo-controlled studies have been conducted over the course
of more than 25 years, which produced mixed, but nevertheless, intriguing results. For
example, studies assessing men family history positive (FH+) for alcoholism report
lower SHAS measures than family history negative (FH-) individuals (Schuckit et al.
1980). Years later, a cross-generational sample of 25 men from the previously
mentioned study and 40 of their offspring showed there was a trending but nonsignificant positive correlation between the SR of fathers and sons of FH+ groups, which
was mirrored by FH- subjects (Schuckit et al. 2005). This provided credence to the idea
that SR may be heritable trait. Follow up studies were conducted over the course of 25
years, taking assessments at the 10-, 15-. 20-, and 25-year marks, further supporting
the predictive power of LLR for future alcohol related problems (Schuckit, 1998;
Schuckit & Smith,1996, 1997, 2000, 2001a,b, 2004, 2006; Schuckit et al. 2004;Trim et
al. 2009). The parameters of these studies were regularly updated with additional
behavioral domains of functioning (behavioral under-control, coping, drinking
environment, etc.) as knowledge in the alcohol research field increased. Some of these
behavioral domains independently predicted development of AUDs, but none were
related to family history status, as was the case for LLR. None of these domains
interacted with LLR in predicting alcoholism indicating that the LLR phenotype is a
completely independent risk factor. Moreover, LLR appeared to be unique to AUDs
because family history of alcoholism status did not show significant correlation with any
other forms of substance abuse or psychopathologies, thus demonstrating that is an
alcohol-specific phenomenon (Schuckit 1994a,b). The alternative view of SR, the
Differentiator Model (DM), asserts that an individual’s risk depends on the degree of
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their response to the stimulating and depressing effects of alcohol during the ascending
and descending limbs of the BAL time course, respectively (King et al. 1993, Newlin &
Thompson 1990, Morean & Corbin, 2010). While the DM theory has not been as
heavily studied as LLR, evidence does exist that supports this particular view. For
instance, a small cohort of FH+ individuals showed significantly increased response to
the stimulating effects of alcohol from baseline compared to FH- individuals (Erblich et
al. 2003). Furthermore, a separate study of non-treatment seeking alcoholics showed
that these subjects had an increasing response to the stimulating effects of alcohol over
time compared to non-alcoholics whose level of response remained stable during the
same period of time (Thomas et al. 2004). In placebo-controlled studies, FH+ males
reported feeling more intoxicated compared to FH- subjects. Another study also
showed that heavy drinkers receiving a high alcohol dose, low alcohol dose, or placebo
reported a sharp increase in the stimulant effects from the higher alcohol dose earlier in
the ascending limb of the BAL compared to light drinkers, who reported no change
between doses (Kaplan et al. 1988). While the DM is a relatively less popular theory
compared to the LLR model, its importance cannot be overlooked, especially since it
does not suffer from some of the caveats found in the LLR model. For instance, the DM
uses the BAES as its primary assessment tool, which was specifically designed for the
assessment of alcohol’s effects, unlike the SHAS measurements used by LLR studies.
Another disadvantage in the LLR model is that it mainly focuses on sedative and other
“negative” experiences associated with the descending limbs of the BAL curves. This
may explain why the strongest results in the LLR studies were only obtained at low
doses of alcohol. This issue is addressed by the DM, which incorporates the more
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“positive” effects that are commonly associated with motivation for heavy alcohol
consumption, thus making this model comparatively more comprehensive. However,
both models suffer from caveats, mostly methodical in nature, that hinder their
respective interpretations. Such limitations extend from differences in alcohol
administration procedures, the number and time of assessments, and measures from
SR assessment across studies. Another major (but ethically necessary) limitation is the
limited age range of subjects, since they must be at least 21 to participate and often
show considerable drinking experience by the time of the study. This creates another
variable regarding tolerance. Despite all this, each of these models, their shortcomings
notwithstanding, have contributed a great deal to our current understanding of risks for
developing AUDs and continue to provide important information in learning how to
approach the treatment of these disorders.

2.2.

Behavioral Models of Alcohol Dependence in mice
Because addiction is a phenomenon unique to humans, no animal model exists

that can encompass all of the characteristics of alcoholism in its entirety. Nevertheless,
some of these characteristics can be satisfactorily modeled in laboratory animals
enough to provide important information on the neurobiological mechanisms that drive
such behaviors (Sanchis-Segura et al. 2006). The development of alcohol addiction is
viewed as three progressive phases (Vengeliene et al. 2008) from the initiation of
alcohol drinking (initiation), to the continued maintenance of alcohol consumption
(maintenance), and finally, the loss of control of alcohol consumption (compulsive
drinking). Again, while addiction cannot be comprehensively replicated in animal
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models, a variety of approaches are used to capture aspects of certain behaviors that
are also featured in humans during each of these phases. Testing initial sensitivity to
the behavioral effects of acute ethanol exposure, for example, can provide insight on
genetic contributions to initiation of drinking (see Crabbe 2005, 2010 for review), while
ethanol consumption and withdrawal studies can provide information on the
maintenance and compulsive phases of drinking (see Sanchis-Segura & Spanagel 2006
for review). The following is an overview of common approaches used in alcohol
research for each of these phases, with particular emphasis placed on the models we
chose to use for our own studies.

2.2.1. Acute ethanol-responsive behaviors
Models of acute ethanol-responsive behaviors are key to studying the genetics of
alcoholism, especially due to the implications that initial sensitivity to ethanol exposure
may have on the level of response in humans, a highly predictive phenotype of future
drinking behavior (Schuckit & Smith, 2011; Schuckit et al. 2011). Ethanol elicits many
responses after acute administration in the mouse and different responses to ethanol
have different genetic regulation suggesting that alcohol sensitivity cannot be evaluated
using a single test (DeFries et al., 1989). The most widely used indices of behavioral
sensitivity include ethanol-induced loss of righting reflex (LORR), hypothermia,
locomotor activity and behaviors categorically referred to as “ataxia” (i.e. rotorod),
(Crabbe et al. 2005, 2012). In addition to ethanol-induced hypothermia, we also chose
to assess ethanol’s hypnotic effects using the LORR assay for our studies. This was
implemented by treating mice with a high dose of ethanol and then determining the
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amount of time the subject took to lose its ability to stand upright (LORR onset) and the
amount of time it took for the subject to right itself three times within 30 sec, which
indicated recovery from these effects (LORR duration). We chose to study both
hypothermia and LORR for a few reasons. These behaviors have been used for years
as behavioral measures for identifying genetically codetermined responses to ethanol
sensitivity, which is an important factor in determining future drinking behavior.
Thermoregulation offers an attractive system for studying ethanol sensitivity, tolerance
and physical dependence to ethanol (Crabbe et al.1989). While exact molecular
mechanisms underlying this response is generally unknown, data suggests that ethanol
and nicotine are influenced by genetic factors, including nAChRs, which have been
shown to play an important role in the maintenance of core body temperature (Crabbe
et al.1989, Sack et al. 2005). Moreover, it was advantageous to use this measure in
conjunction with LORR due to the fact that core body temperature has been found to
modulate behavioral sensitivity to ethanol-induced LORR, as there appears to be a
negative correlation between hypothermia and LORR duration (Crabbe et al. 1983,
1994). Another advantage in using these models is that they are relatively
straightforward in their implementation and often do not require a great deal of technical
knowledge to employ them.
We also sought to explore changes in the reward-related effects and anxiolyticlike behavior induced by ethanol using the conditioned place preference (CPP) and
elevated plus maze (EPM) paradigms, respectively. The types of responses these
assays model are especially pivotal in the search for understanding motivation for
obtaining alcohol. It is known alcohol is often consumed for its rewarding effects, and
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alcoholism also appears to be highly co-morbid with anxiety, among several other
psychiatric disorders (Loas et al. 2002, Segui et al. 2001, Hahesy et al. 2002, Perugi et
al. 2002). Furthermore, increased ethanol intake has been positively correlated to
anxiety-like behavior in humans and animals (Boyce-Rustay et al. 2007; Lopez et al.
2011; Ploj et al. 2003, Sanna et al. 2011, Brown et al. 1995, Dawson et al. 2005,
Kuntsche et al. 2009, Linsky et al. 1985, Nesic & Duka, 2006, Stevens et al. 2008).
CPP and EPM are models that have been used extensively in the respective study of
the rewarding and anxiolytic properties of drugs of abuse including ethanol (SanchisSegura et al. 2006, Hart et al. 2010). While none of the listed models measure drinking
behavior directly, such tests remain important to alcohol research because they provide
convergent data on genes and their contribution to the acute effects of intoxicating
doses of ethanol. These tests are often used across multiple panels of geneticallyinbred rodents in the identification of genomic locations of genes influencing their
respective responses, known as Quantitative Trait Loci (QTL). Proving genes within
these QTL regions could be important in discovering pathways that can be targeted for
pharmacotherapies in humans (Crabbe et al. 2005, 2006b). While these approaches
provide some important insight in the contribution of particular genes to ethanolresponsive behaviors, the results of such assays must be interpreted with caution due
to the sensitivity of these acute assays to procedural variation and the genetic
backgrounds of the animals chosen for study (Crabbe et al. 2006b, Lim et al. 2012).
2.2.2. Mouse models of ethanol intake
Ethanol self-administration models are among the most widely used procedures
in research on the maintenance of ethanol consumption, quite simply because they
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provide the most direct insight on the conditions that may motivate a subject to drink.
Consequently, they can be used as adequate models for discovering common neural
mechanisms involved in drinking behavior and can, therefore, help identify therapeutic
strategies for treating AUDs (Sanchis-Segura et al. 2006). Self-administration models
are broadly categorized as either operant or non-operant procedures, the latter
commonly reporting the amount of drug consumed while the former focuses on the
behavioral response itself. In operant self-administration procedures, subjects are
enclosed in an "operant box” consisting of devices that deliver the drug reinforcer (in
this case, ethanol) and transmit the operant response. The subject is placed under a
schedule of reinforcement where it has to perform a certain task in a given time period
to obtain the reinforcer. While operant behavioral models are acknowledged as viable
tools for assessing alcohol self-administration, non-operant, oral self-administration
procedures are the more frequently featured models in alcohol drinking studies
(Spanagel et al. 2000). This was the particular model of choice for our experiments.
The procedure is traditionally employed using a two-bottle choice paradigm where the
subject is presented with one water bottle and one ethanol bottle (normally 10 - 20%),
simultaneously, and is monitored for daily intake (in g/kg) and/or preference (expressed
as the proportion of ethanol to total fluid intake). Additionally, multiple variables such as
temporal accessibility, availability of multiple concentrations of ethanol, and others can
be adjusted based on the nature of the data desired. These models do not require
sophisticated equipment or major technical expertise making them an attractive method
for assessing ethanol consuming behavior. Furthermore, they display high face validity
in that they mimic some aspects of real human behavior, as well as predictive validity,
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since some drugs identified for reducing ethanol consumption in animals in these
paradigms also reduced alcohol consumption when tested in humans during clinical
trials (Sanchis-Segura et al. 2006; Spanagel et al. 2000, 2009). However, a few
limitations of this approach are worthy of mention. First, is the inability to make
unidirectional interpretations from results since such models provide information only
about the consumption of a rewarding drug without being able to distinguish between
distinct factors (i.e. drinking patterns) that contribute to the behavior. This is especially
true under conditions of unrestricted access, which we used for our studies. Second,
human intervention can introduce variability into the experiment, which may obscure
results and make reproducibility difficult in some instances. These disadvantages can
be addressed by complementing studies with data from operant self-administration
procedures, as well as using devices such as lickometers, allowing increased flexibility
of experimental design and reducing the need for the experimenter to be present during
testing.
Perhaps the most significant shortcoming of the previously mentioned selfadministration methods, however, is their inability to compel animal subjects to drink to
the point of intoxication, even after prolonged periods of exposure. Thus, while such
models are suited for studying maintenance of ethanol drinking behavior, they do not
produce key traits that reflect compulsive drinking behavior such as alcohol seeking,
and withdrawal. Because of this, work continues to be done to identify methods that are
able to model this important phase of the alcohol addiction cycle. In order to achieve
the desired behavior, the animal often must first be made physically dependent to
ethanol. This has traditionally been achieved through the implementation of ethanol
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bolus injections (McQuarrie & Fingl, 1958) or intragastic infusions (Majchrowicz, 1975) ,
as well as ethanol liquid diet (Tabakoff et al. 1977) or vapor chambers (Goldstein & Pal,
1971) to induce more severe dependence. Soon after ethanol administration ceases,
observable withdrawal effects, such as handling-induced convulsions appear that can
be used to assess the level of dependence. All of these serve as viable options for
studying the behavioral effects of ethanol withdrawal directly in rodents because
observable withdrawal symptoms similar to humans will appear soon after ethanol
administration ceases (Friedman et al. 1980). However, the disadvantage to these
approaches is that dependence is achieved through passive ethanol administration
instead of developing naturally in the subject through active consumption. This not only
limits the interpretations made by withdrawal studies, but also, provides no data
whatsoever on the drinking patterns required to achieve this state of dependence.
Thus, models more conducive to measuring such changes have been developed in the
past decade in order to address these concerns. We chose two of these models,
Drinking-in-the-Dark and Intermittent Access, in our studies as a way to supplement our
results with the traditional two-bottle choice oral self-administration model. Drinking-inthe-Dark (DID) is a limited-access model of acute binge drinking behavior in which
animals are briefly exposed to one bottle containing a high concentration of ethanol
(~20%). Subjects are exposed to ethanol a few hours into the dark cycle since this is a
window of high activity in rodents (Rhodes et al. 2005, Goldstein & Kakihana, 1977;
Freund, 1970; Millard & Dole, 1983; Kurokawa et al. 2000). Studies show that subjects
under these conditions, particularly mice selectively bred to prefer ethanol solutions, will
reliably self-administer ethanol to achieve blood ethanol concentrations (BEC) in excess
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of 1.0 mg/ml, enough to cause measurable behavioral intoxication (Rhodes et al. 2005,
2007). While this is a noteworthy improvement on the standard two-bottle choice
procedure, there is a trade-off in that it involves the removal of choice, thus diminishing
the external validity of the assay much like the other methods of ethanol dependence
induction (Hwa et al. 2011). This has prompted the development of alternative methods
such as the Ethanol Deprivation Effect (EDE) and Intermittent Access (IA) models in an
attempt to induce escalated ethanol drinking in a way that more closely reflects human
behavior. Both methods are based on consistent observations that renewed access to
ethanol after a period of deprivation will cause a pronounced, albeit, temporary
escalation of ethanol drinking (Spanagel et al. 2000, Rodd et al. 2004). The EDE has
been observed across many animal species including rats (Khisti et al. 2006, McKinzie
et al. 1998; Rodd-Henricks et al. 2000, Sinclair & Senter, 1979), mice (Salimov et
al.1993), monkeys (Kornet et al.1990; Sinclair, 1971), and humans (Burish et al. 1981;
Mello & Mendelson, 1972) and IA, while comparatively less studies in animals exist,
appears to be a common feature in conditions that promote excessive drinking in
humans as well (Hwa et al. 2011). Each procedure is conducted in a similar manner to
standard the two-bottle choice test, but subjects undergo specified deprivation periods
where ethanol is removed from their home cages. In EDE studies, the deprivation
period implemented can range from days to weeks and often is used as a model of
ethanol craving and relapse (Sanchis-Segura et al. 2006, Le & Shaham 2002, Khisti et
al. 2006, Sinclair et al. 1968; Spanagel & Holter, 1999)
In the IA procedure, the deprivation period is usually implemented every other
day, as was done in our studies. Furthermore, repeated episodes of deprivation over
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time may enhance ensuing withdrawal symptoms, which is thought to increase the
compulsion to consume more ethanol (Hwa et al. 2011). Thus, the method was
developed with the intention not solely to induce escalated drinking behavior, but to
induce it in such a way that it produces measurable withdrawal symptoms. Indeed,
studies show that mice selectively bred for high ethanol preference do achieve intake
levels comparable to DID, and can lead to detectable withdrawal symptoms after
months of testing (Melendez et al. 2006, 2011; Hwa et al. 2011).

2.2.3. The mouse as an animal model to study the role of nicotinic receptors in
ethanol behavioral effects
Choosing the appropriate animal model for study is another important factor to
consider when employing the techniques described above. The utility of the mouse as
a model of human disease is substantial due to the nearly 80% similarities between
mouse and human genomes (Crabbe et al.2005, Doyle et al. 2012). Additionally,
experimenters can exert a high degree of genetic and environmental control over
subjects, and their short intergenerational intervals, robust litter sizes, and defined
health histories make them excellent models for examining the genetic underpinnings of
mammalian diseases (Doyle et al. 2012). There are a wide variety of the genetic
backgrounds from which each mouse model originates, with each displaying distinctive
phenotypes in their responses to drugs of abuse. Two lines that are particularly
highlighted in alcohol studies are those of the C57BL/6 (B6) and DBA/2 (D2)
backgrounds. These are two of the most commonly used strains in neuroscience
research, and are notable for their pronounced differences in ethanol consumption (Lim
38

et al. 2012, McClearn et al. 1959). Additionally, they show marked differences in their
responses to a variety of ethanol’s acute behavioral effects including locomotor activity,
LORR and ataxia, thus making them excellent models of ethanol sensitivity (Phillips et
al. 1995, Metten & Crabbe, 1994; Crabbe et al. 2003, 2006a, Cunningham et al. 1992).
For our studies, we chose the B6 model for several reasons. First, highly backcrossed
mice from the B6 background are, genetically, nearly homogenous and there is much
phenotypic data available for wild-type B6 mice (Lim et al. 2012). Second, mice from
this background display high preference for ethanol solutions and have long been
documented to readily self-administer relatively high quantities of ethanol (McClearn et
al. 1959). A third important advantage of using B6 mice is the ability to use gene
targeting methods, particularly gene deletion to produce knockout (KO) mice that can
enhance our understanding of ethanol-induced behavioral changes that occur in the
absence of a specified gene. KO mice have been used extensively in alcohol research
to identify critical molecular components involved in ethanol-responsive phenotypes.
KO mouse studies have been seminal in identifying the contribution of
neurotransmitter/neuropeptides systems underlying addiction-related behaviors
including GABA, glutamate, monoamines, opioids, and endocannabioids as well as
intracellular signaling proteins (see Spanagel et al. 2009 for review).
The use of KO mice was especially necessary for our investigation of α5*
nAChRs since there are currently no available selective antagonists for this particular
subtype. These mice are produced in a two-stage process utilizing pluripotent
embryonic stem (ES) cells to proliferate induced inheritable genetic changes in many
successive generations. They were engineered by replacing the gene of interest with a
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neomycin resistance cassette via homologous recombination in ES cells from 129/SvJ
mice (Salas et al. 2003). The ES cells that have successfully undergone a targeting
event are selected and transferred into blastocyst embryos of the B6 surrogate mother
from which chimeras containing the KO allele are derived. These chimeras are then
mated with B6 mice to transmit the KO allele to later generations. To date, a variety of
nAChR KO mice, in addition to α5, have been produced including
α2, α3, α4, α6, α7, α10, β2, β3 and β4 (Xu et al. 1999a, Marubio et al. 1999, Ross et al.
2000, Chaptiaux et al. 2002, Orr-Urteger et al. 1997, Vetter et al. 1999, Picciotto et al.
1995, Booker et al. 1999, Xu et al. 1999b).
Despite the enormous utility of these genetic KO mice, however, there are
limitations that must be considered when taking this approach. Most notably is the
issue of developmental compensation that inevitably occurs with the deletion of a gene.
This physiological response can potentially cloud interpretations as the resulting
phenotypes could be due either to gene deletion or to developmental changes set in
motion by gene deletion that have nothing to do with the drug treatment. A potential
example of this is changes in the expression levels of other nAChR subunits when one
subunit gene is deleted. Fortunately, however, previous literature show negligible
changes in expression level and enzyme function in many nAChR subunit KO animals,
including α5 mice, of various backgrounds (Picciotto et al. 1995, Marubio et al. 1999,
Ross et al. 2000, Salas et al. 1995, Chaptiaux et al. 2002). Another minor, but
considerable issue that may arise is discrepancies in behavioral results due to the
genetic background of the mouse strain used for breeding (Nadeau et al 2001). Though
most nAChR KO mice are backcrossed with the B6 mouse strain, it is important to note
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that the use of other strains for backcrossing the mutations may results in different
phenotypes. The effects of these discrepancies can be minimized by ensuring the use
of mice with an identical genetic background throughout studies with knowledge of the
behavioral phenotypes that characterize the background strain. We made certain to
adhere to these conditions in our studies.

2.2.4 Dissertation Hypotheses and Objectives
While it remains to be seen which nAChR subtype(s) is(are) most crucial in
mediating ethanol’s behavioral effects, it appears evident that cholinergic signaling
plays a potentially significant role in ethanol-responsive behaviors. Therefore, the main
goal of this thesis is to more fully characterize specific nAChR subtypes involved in
mediating ethanol-responsive behaviors in acute administration of ethanol as well as
chronic drinking behavior in mice. Particularly, we would like to provide further in vivo
evidence for the human data suggesting a potential role, if any, for α5* nAChRs in
influencing the ethanol’s acute effects and ethanol consumption in mice as well as
identify the specific contribution of these nAChRs to such behaviors. Additionally, we
aim to further characterize the role of β2* nAChRs in mediating ethanol-responsive
behaviors, due the close of association of the α5 subunit to the β2 subtype, and their
integral role in dependence to nicotine, a drug highly co-morbid with alcohol abuse. We
hypothesize that decreased α5* nAChR expression by removal of the α5 gene will alter
the effects of acute ethanol exposure as well as ethanol drinking in high ethanolpreferring C57BL/6J mice. Specifically, we believe that acute ethanol-responsive
41

behavior will be enhanced in absence of the α5 gene, while drinking behavior will be
attenuated by these conditions. We further hypothesize that α5* nAChRs mediate their
effects through their association with β2* nAChRs in the acute effects with ethanol, but
not necessarily in chronic ethanol drinking.

42

CHAPTER 3: CHARACTERIZATION OF α5*
α5 NICOTINIC ACETYLCHOLINE
RECEPTORS IN ETHANOL-RESPONSIVE BEHAVIORS

3.1

Introduction
Alcohol (ethanol) and nicotine are two of the most commonly abused substances

in society. These drugs cause over 500,000 deaths annually in the United States, with
associated medical costs in excess of $200 billion dollars per year (Harwood et al.
1998, Epping-Jordan et al. 1998, Li et al. 2007). There is 50-80% smoking rate found
among alcoholics, and the high co-morbidity of use associated with these two drugs
increases the difficulty of achieving long-term abstinence with either (Hurt et al. 1994,
Pomerleau et al. 1997, Romberger & Grant, 2004, Larsson et al. 2004a). Evidence in
both humans and in animals support that there are at least some common genetic
elements underlying these disorders (Swan et al. 1997, True et al. 1999). In addition,
alcohol has been shown to interact with various nicotinic acetylcholine receptors
(nAChR) subtypes in expressed systems and in the brain (see Davis & de Fiebre, 2006
for review). In light of such evidence, it is probable that nAChRs play an important role
in alcohol-mediated behaviors.
Neuronal nAChRs are ligand-gated ion channels that can form multiple nAChR
subtype combinations containing α (α2−α10) and/or β (β2−β4) subunits.

They are

expressed as a combination of α2 to α6 and β2 to β4 subunits in the heteromeric form
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or as α7 to α10 subunits in the homomeric form. The most widely expressed and bestcharacterized subtype is α4β2* (* denotes the presence of additional subunits) which
has a high affinity for nicotine and is thought to be a principle mediator of its rewarding
properties (Picciotto et al. 1998; Tapper et al. 2004). Mounting evidence suggest that
these subtypes modulate several of the acute in vivo effects of alcohol in mice (Owens
et al. 2003, Butt et al. 2004; Dawson et al. 2013) while playing no significant role in
alcohol intake and reward (Hendrickson et al. 2009; Kuzmin et al. 2009; Kamens et al.
2010a,b; Dawson et al. 2013). Recent investigations into the CHRNA5-A3-B4 genomic
region, a region coding for α5* subunits have yielded some interesting observations with
respect to nicotine and alcohol dependence. For example, studies show that functional
variation in α5∗ nAChRs and steady state mRNA levels are associated with alcohol
dependence risk in humans and ethanol preference in rodents (Wang et al.2009,
Symons et al. 2010). Additionally, variance in this genomic region is also associated
with the level of response to ethanol as well as age of initiation of ethanol and tobacco
use, which each serve as significant predictors of future drug abuse liability (Joslyn et
al. 2008, Schlaepfer et al. 2008, Schuckit & Smith, 2011; Schuckit et al. 2011).
Despite their limited distribution, α5* nAChRs can have a substantial functional
impact on signaling in the brain (Kuryatov et al. 2008, Grady et al. 2010).

It is

noteworthy that α5 subunits are accessory subunits that are known to modify the
properties of α4- or α3-containing nAChRs respectively (Grady et al. 2010; Kuryatov et
al. 2011; George et al. 2012). The α5 subunits can co-assemble with both α4β2*and
α3β4* nAChRs (Gotti et al. 2006b, 2007, Collins et al. 1996, Picciotto et al. 1998) and
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have demonstrated significant involvement in nicotine intake, reward, and withdrawal in
rodents (Salas et al. 2004; Jackson et al. 2010, Jackson et al. 2008; Fowler et al. 2011).
Given its functional impact on these particular subtypes, α5 is in a unique position to be
an influential component in alcohol dependence-related behaviors.

Recent data in

support of this notion demonstrates that α5 nAChR gene deletion does, indeed,
modulate the sedative effects produced by acute ethanol administration in mice without
playing a role in the drug consumption the Drinking-in-the-Dark (DID) paradigm (Santos
et al. 2012). Despite this initial report, more work is needed to further elucidate the role
α5* nAChRs play in mediating phenotypes associated with alcohol dependence.
The aim of these studies was to further characterize the role of α5* nAChRs in
ethanol’s various behavioral effects in the mouse. In light of genetic and behavioral
evidence showing an association of the α5 gene to level of response to acute ethanol
exposure, we chose a battery of tests measuring the initial response to acute ethanol
administration in the α5 subunit deficient mice. Namely, we chose to test for changes in
response to the effects of high ethanol exposure including the hypothermia and loss of
righting reflex, as well as test for changes in a more complex behavior, anxiolytic –like
behavior in mice. Furthermore, we determined ethanol intake in a variety of ethanol
consumption models in mice.
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3.2

Methods

Animals
Mice null for the α5 subunit (α5−/− ) and their wild-type (α5+/+) littermates were
purchased from Jackson laboratories (Bar Harbor, ME) and bred in an animal care
facility at Virginia Commonwealth University. Mutant and wild types were obtained from
crossing heterozygote (α5+/− ) mice with C57Bl/6J mice. For all experiments, mice were
backcrossed at least 8 to 10 generations.

Mice were housed in a 21°C humidity-

controlled Association for Assessment and Accreditation of Laboratory Animal Care
(AALAC)-approved animal care facility. They were housed in groups of six and had free
access to food and water. The rooms were on a 12-h light/dark cycle (lights on at 6:00
a.m.). Mice were 8–10 weeks of age and weighed approximately 20–25 g at the start of
all the experiments. All experiments were performed during the light cycle (between
6:00 a.m. and 6:00 p.m.) and the study was approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University. All studies were carried out
in accordance with the National Institute of Health guide for the Care and Use of
Laboratory animals.

Drugs
(-)-Nicotine hydrogen tartrate salt were purchased from Sigma-Aldrich Inc. (St. Louis, MO,
USA). Nicotine was dissolved in 0.9% saline and delivered subcutaneously (s.c.), at a
volume of 10 ml/kg body weight. Ethanol was also dissolved in 0.9% saline and prepared
as a 20% (v/v) solution which were delivered via intraperitoneal (i.p.) injection for acute
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experiments or per os (p.o.) for drinking experiments. Ethanol doses (2.0 – 3.5 g/kg) were
chosen based on effective doses obtained in dose response curves conducted before each
study, which were consistent with those found in literature (Alanka et al.1992, Browman et
al.2000).

Body Temperature Measurement
Hypothermia induced by acute ethanol was measured using a standard rectal thermometer
(Fischer Scientific, Pittsburg, PA) with probe (inserted ~24 mm). Five mins after baseline
temperatures were recorded, α5−/− and α5+/+ mice were administered 3.0 g/kg ethanol or
saline (i.p.). Body temperature measurements 15- and 60 min-post ethanol injection were
recorded in degrees Celsius (Co). Data was expressed as mean ± SEM of the difference in
rectal temperature before and after ethanol treatment. The ambient temperature of the
laboratory varied from 21-24°C from day to day.

Loss of Righting Reflex (LORR)
The sedative-hypnotic effects of ethanol were measured using the loss of righting reflex
assay (LORR). α5−/− and α5+/+ mice were administered ethanol or saline (i.p.), then were
monitored for initial LORR and placed in a supine position in a V-shaped trough. A subject
was confirmed to have achieved LORR only after it was on its back for at least 30 seconds.
Because this reflects aspects of initial sensitivity and acute functional tolerance
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(Ponomarev & Crabbe 2002a), two LORR scores were reported for each subject. The first
was the total time from ethanol injection until initial LORR, which was reported as latency to
LORR. The second was total time required for the subject to right itself 3 times within 30
seconds from the onset of LORR, which was reported as the time required to right. Mice
taking longer than 5 minutes to experience LORR were eliminated from the study due to
the possibility of misplaced injection. Data (mean ± SEM) were expressed as latency to
LORR and time required to recover in seconds.

Elevated Plus Maze (EPM)
Reduction in anxiety-like behavior induced by acute ethanol was assessed using the
elevated plus maze apparatus. This is an elevated platform consisting of two crossbars
that create four arms. Two of these arms have walls (closed arms) and the other two arms
are exposed (open arms).

Because mice commonly display an innate fear of open,

elevated places, an increase in the amount of time spent in the open arms is thought to
represent a reduction in anxiety-like behavior. Mice were given at least 12 hrs to acclimate
to the testing room. On test day, α5−/− and α5+/+ mice were administered ethanol or saline
(i.p.). Subjects were then returned to their home cage for 15 minutes to allow ethanol to
take effect and to avoid any hyperlocomotion from stress caused by the injection. Each
subject was then placed briefly in a plastic container and transferred to the center of the
maze. The subject was then allowed to freely explore the apparatus for 5 minutes, with
time starting immediately after placement in the center of the maze. Data (mean ± SEM)
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were expressed as the total time spent in the open arms in seconds. The number of
crossovers was also recorded to account for any changes in locomotor activity.

Two-Bottle Choice
Drinking behavior was assessed using a standard two-bottle choice procedure. Mice were
housed individually in cages and allowed to acclimate to the test room one week prior to
the experiment. Cages contained two 10-ml pipettes filled with water fitted with a double
ball-bearing metal sipper tube and rubber stopper on opposite ends. At the end of the
acclimation week, one water tube was replaced with 3% (w/v) ethanol providing a choice of
ethanol or water with 24-hr access for 4 days. Following exposure to 3% (w/v) ethanol, the
ethanol concentration was incrementally increased to 6-, 10-, 15- and 30% (w/v) every 4
days to determine the effects of ethanol concentration on intake and preference.
Additionally, ethanol and water tubes were placed on two empty cages, which allowed for
measurement of leakage and evaporation from the tubes. The average volume depleted
from these “control” tubes was subtracted from the individual drinking volumes each day
before data analysis. Intake was reported as g/kg ethanol consumed and preference as
the ratio of ethanol consumed divided by total amount of ethanol and water fluid intake
(ml), combined. Additional measurements including body weight (g) and total fluid intake
(ml) were also recorded. Data (mean ± SEM) were expressed as total intake or preference
ratio.

Intermittent Access
49

Chronic ethanol drinking behavior was also assessed using the intermittent access (IA)
procedure as previously described (Hwa et al.2011; Dawson et al.2013). This procedure is
advantageous over the traditional two-bottle choice drinking procedure in that it produces
escalation in ethanol drinking by repeated deprivation cycles thus better approximating
human drinking behavior (Rodd et al. 2004). Briefly, α5−/− and α5+/+ mice were housed
individually in cages one week prior to testing with ad libitum access to food and water.
Three days before the end of acclimation week, water bottles were replaced with two
drinking tubes, made from 10-ml serological pipettes containing a double bearing sipper
tube and a rubber stopper on either end of the tube, filled with water. At the end of the
acclimation period, one water tube was replaced with one ethanol filled with 3-, 6-, and
10% w/v ethanol on alternating days (Sunday, Tuesday, and Thursday) while two water
tubes were presented on the deprivation days (Monday, Wednesday, Friday, and Saturday;
Table 1). After one week, 20% (w/v) ethanol tubes were presented on alternating days
(Sunday, Tuesday, and Thursday) for the remainder of the experiment. Control mice were
presented with continuous access to ethanol by presenting one 3% (w/v) ethanol tube on
Sunday and Monday, 6% Tuesday and Wednesday, and 10% (w/v) ethanol Thursday,
Friday, and Saturday. After one week, 20% (w/v) ethanol tubes were presented daily for
the remainder of the experiment. Additionally, ethanol and water tubes were placed on two
empty cages, which allowed for measurement of leakage and evaporation from the tubes.
The average volume depleted from these “control” tubes was subtracted from the individual
drinking volumes each day before data analysis. Intake was reported as g/kg ethanol
consumed and preference as the ratio between of ethanol consumed divided by total
amount of ethanol and water fluid intake (ml), combined.
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Additional measurements

including body weight (g) and total fluid intake (ml) were also recorded. Data (mean ±
SEM) were expressed as total intake or preference ratio.

Drinking-in-the-Dark (DID)
DID is a limited access drinking procedure that was used to assess sub-chronic bingedrinking behavior in mice. As previously described (Hendrickson et al.2009), α5−/− and
α5+/+ mice were housed individually in cages one week prior to testing with ad libitum
access to food and water.

Because mice in general are shown to display maximal

expression of consumatory behavior a few hours into the dark cycle (Rhodes et al.2005),
subjects were housed under a reverse light-dark cycle (7am – 7pm) in order to facilitate for
daytime testing. At the end of the acclimation period, the water bottle from each cage was
replaced with one drinking tube containing 20% (w/v) ethanol three hours after lights off
(10am). Baseline intake was measured at 2- and 4-hrs after ethanol presentation for two
days. Additionally, due to evidence that α5 gene deletion alters nicotine self-administration
behavior, we also wanted to determine the effect of sub-chronic nicotine injections on α5
mice in DID drinking behavior. Therefore, after obtaining the previously described baseline
intake measurements, each genotype was separated into two groups receiving either
saline or 0.5 mg/kg nicotine (s.c.) treatment. Each respective group was treated once a
day immediately before presentation of ethanol for a total of 4 days, with measurements
reported at 2- and 4-hrs after presentation of ethanol. All mice were treated with injections
of saline for two days before testing in an attempt to acclimate them to the stress of the
injections. On the last day of testing, one 10 µl blood sample was taken via cheek punch
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using 4mm Lancets and stored in BD microtubes to determine blood ethanol
concentrations after four hours limited access to ethanol.

Data (mean ± SEM) were

expressed as total intake (g/kg) and blood ethanol concentration (mg/ml).

Blood Ethanol Concentration (BEC) Analysis
To rule out the possibility of any observed effects being due to deletion of the α5 gene
changing BEC levels, we mice tested for their BEC in a two-hour time course after
receiving one high dose of ethanol.

Drug naïve α5−/− and α5+/+ mice were given a single

challenge injection of 4.0 g/kg ethanol (i.p) and returned to their home cages. Mice were
separated into groups in which one 10 µl blood sample was taken via cheek punch using
4mm Lancets (Medipoint, Inc., Minenola, NY) at 15-, 30-, 60- or 120 min time-points after
injection.

The blood was stored in BD microtainers and analyzed using Gas

Chromatography similar to a previously described procedure (Gallaher et al.1996). Data
(mean ± SEM) were expressed as BEC in mg/ml.

Conditioned place preference (CPP)
An unbiased CPP paradigm was used in this study to assess rewarding characteristics
of ethanol. The place-conditioning chambers consisted of two distinct compartments
separated by a smaller intermediate compartment with openings allowing access to
either side of the chamber. On day 1, animals were confined to the intermediate
compartment for a 5-min habituation period, and then they were allowed to move freely
between compartments for 15 min. Time spent in each compartment was recorded.
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These data were used to separate the animals into groups of approximately equal bias.
Days 2 to 4 were the conditioning days during which the saline group received saline in
both compartments and drug groups received ethanol (i.p.) in one compartment and
saline in the opposite compartment. Drug-paired compartments were randomized
among all groups. Activity counts and time spent on each side were recorded via
photosensors using interface and software (MED Associates, St. Albans, VT). Data
were expressed as difference in time spent on drug-paired side on test day (Day 5) and
habiutation day (Day 1). A positive number indicated a preference for the drug-paired
side, whereas a negative number indicated an aversion to the drug-paired side. A
number at or near zero indicated no preference for either side.

Statistical Analysis
Primary dependent variables for LORR were latency to and duration of LORR and time
spent in opent arms for EPM. For CPP, the primary dependent variable was the
preference score. Data were analyzed using standard one way analysis of variance
(ANOVA) with genotype as the independent variable . For hypothermia, the dependent
varable was change in body temperature and analyzed using standard one-way
repeated measures (ANOVA) with genotype and time point as the independent
variables . Each analysis was followed by Bonferroni post-hoc tests to further analyze
significant data with the alpha level set at 0.05. For two-bottle choice, ethanol
consumption, water consumption, and total fluid consumption were used as primary
dependent variables. Data were analyzed using factorial analysis of variance (ANOVA)
with the alpha level set at 0.05 with strain, dose, time, and concentration were possible
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variables. Interactions involving multiple factors were examined using successive
ANOVAs including fewer factors. Significant two-way interactions were followed up with
Bonferroni post-hoc tests to further analyze significant data with the alpha level set at
0.05.

3.3

Results

Body Temperature Measurement
Treatment with 3.0 g/kg ethanol had the intended effect of inducing a significant drop in
body temperature (Figure 4). Three-way repeated measures ANOVA (genotype x
treatment x time) revealed a significant main effect of genotype [F (1,19) = 5.376; p=
0.0317] and [F (1,19) = 66.028; p< 0.0001], and a marginal, but non-significant effect of
time [F (1,19) = 3.300; p= 0.0851]. A genotype x time interaction was the only
significant interaction detected [F (1,19) = 5.057; p= 0.031]. Subsequent one-way
ANOVA analysis of genotype conducted at each time point revealed that ethanolinduced hypothermia significantly differed in α5−/− mice vs. α5+/+ control animals at the
60-min [F (1,10) = 5.976; p= 0.0346], but not 15-min, [F (1,10) = 2.973; p= 0.1154] postethanol injection, indicating that α5−/− experienced increased ethanol hypothermia only
at the 60 min time point . The data thus shows that deletion of the α5 gene confers an
enhanced response to the hypothermic effects of acute ethanol that is not evident until
at least 15 min after exposure.
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Figure 4. Deletion of the Chrna5 gene enhances ethanol-induced hypothermia in C57BL/6J mice.
Data (mean + SEM) represent the change in body temperature from baseline in degrees Celsius
of α5 KO mice at 15- and 60 min time points after receiving an injection of 3.0 g/kg ethanol. N= 6
per group.
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LORR
Delivery of 3.5- and 3.8 g/kg doses of ethanol had the intended effect of inducing LORR (Figure 5).
A two-way ANOVA analysis showed no significant main effects of genotype [F(1,29)= 3.144; p=
0.0867], dose [F(1,29)= 0.714; p= 0.4051], nor interaction [F(1,29)= 0.007; p= 0.9326] on LORR
onset (Figure 5A). However, two-way analysis of LORR duration revealed a significant main effect
of genotype [F(1,29)= 8.298 ; p= 0.0074], post-hoc p< 0.05) and dose [F(1,29)= 11.955; p= 0.017],
post-hoc< 0.05), but not interaction [F(1,29)= 0.264; p= 0.6111) in α5−/− and WT mice (Figure 5B).
Thus, the data show that while ethanol had a dose-dependent effect on LORR duration in
both α5−/− and WT, this response was enhanced in α5−/− mice indicating that deletion of the α5
gene may attenuate tolerance to hypnotic doses of ethanol while not necessarily influencing the
onset of these effects.
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Figure 5. Deletion of the Chrna5 gene enhances ethanol-induced LORR duration while having no
effect on LORR onset in C57BL/6J mice. Data (mean + SEM) represent (A) latency to LORR
onset and (B) total duration of LORR in seconds in α5−/− mice after receiving an injection of 3.8
g/kg ethanol. N= 6-7 per group.
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EPM
As expected, a dose of 2.0 g/kg ethanol caused a significant increase in the amount of time spent
in the open arms in the EPM apparatus (Figure 6). Two-way ANOVA analysis of the amount of
time spent a significant main effect of treatment [F(1,34) = 25.236; p< 0.0001], genotype [F(1,34)=
4.405; p= 0.0433], and interaction ([F(1,34)= 5.491; p= 0.0251], Figure 6A). Subsequent one-way
ANOVA analysis revealed a significant difference in KO mice [F(1,18)= 5.867, p< 0.0262]
compared to ethanol-treated WT mice in the ethanol treated groups. We also analyzed the number
of crossovers to determine if these differences were due to changes in locomotor activity (Figure
6B). Two-way ANOVA (genotype x treatment) analysis of the number of crossovers did not show a
main effect of either genotype [F(1,34) = 0.579; p= 0.4519] or treatment [F(1,34)= 0.1079; p=
0.3063]. There was a marginal interaction, but this was statistically non-significant [F(1,34)= 3.903;
p= 0.0564]. Thus, the data shows that α5−/− mice spent more time in the open arms of the EPM
than their WT counterparts did which indicates that they displayed an enhanced response to those
aspects of ethanol-induced anxiolysis reflected in the EPM. This could mean that deletion of α5
gene modulates at least some of the anxiolytic properties produced by acute ethanol exposure.
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Figure 6. Deletion of the Chrna5 gene enhances ethanol-induced increase in open arm time
without affecting locomotor activity. Data (mean + SEM) represent (A) time spent in open arms in
seconds and (B) total number of crossovers in α5−/− mice after receiving an injection of 2.0 g/kg
ethanol. N= 7-11 per group.
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Conditioned Place Preference (CPP)
The administration of 1.0- and 2.0 g/kg ethanol over the course of the conditioning
phase produced a preference response on test day, as expected (Figure 7). Two-way
ANOVA showed significant main effects of genotype [F(1,27) = 60.27, p< 0.0001], dose
[F(1,27) = 94.52, p< 0.0001], and interaction [F(1,27) = 68.50, p< 0.0001]. Further
analysis of ethanol –treated groups with one-way ANOVA revealed a significant
difference in the preference score between genotypes [F (1, 6) = 19.975; p= 0.0004] as
the preference score displayed by the α5−/− mice was drastically reduced compared to
their α5+/+ counterparts at each dose. The data show that presence of the α5 gene may
be required for the full acquisition of ethanol CPP in mice and, thus, some of the
reward-like effects produced by ethanol.
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Figure 7. Deletion of the Chrna5 gene dose dependently reduces ethanol-induced
increase in CPP without effecting locomotor activity. Data (mean + SEM) represent
time spent on the ethanol-paired side in α5−/− mice on test day after conditioning with
repeated injections of 1.0- and 2.0 g/kg ethanol. N= 6-10 per group.

61

BEC Analysis
As expected, a considerable amount of ethanol in blood was detected at each time-point for up
to 120 mins after ethanol injection (Figure 5). A one-way ANOVA analysis showed no
significant difference between α5

−/−

mice and their WT counterparts at 15-min [F(1,3)= 0.057,

p= 0.8273], 30 min [F(1,3)= 0.2796, p< 0.1931], 60 min [F(1,3)= 2.733, p< 0.1968], nor 120 min
time-points [F(1,3)= 1.587, p< 0.2968] after injection with 4.0 g/kg ethanol. These data suggest
that deletion of the α5 gene does not affect BEC levels in mice, at least at hypnotic doses of
ethanol.
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Figure 8. Deletion of the Chrna5 gene has no effect BEC levels in C57BL/6J mice over
two hour time course. Data (mean + SEM) represent BEC in mg/ml at 15-, 30-, 60- and
120 min time points after receiving an injection of 4.0 g/kg ethanol . N= 3-5 per group.
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Two-Bottle Choice
As expected, mice given free access to ethanol and water displayed a concentrationdependent increase in ethanol intake at a range of 3- to 30% (w/v) ethanol (Figure 9).
Two-way repeated measures ANOVA (concentration x genotype) revealed main significant
effects of concentration [F(1,19)= 16.321, p< 0.0001], but not genotype [F (1,17)= 0.474 ,
p< 0.5005] nor interaction ([F(1,19)= 1.109, p< 0.3397], Figure 9A).

Furthermore, the

concentration-dependent increase in ethanol intake was not due to differences in total fluid
intake between groups as ANOVA analysis showed no difference between groups [F
(2,63)= 0.249, p< 0.7807]. The results for ethanol preference were similar to those of
intake as two-way repeated measures ANOVA (concentration x genotype) revealed main
significant effects of concentration [F (1,19)= 13.432, p< 0.0001], but not genotype [F
(1,17)= 0.285, p= 0.6984 ] nor interaction ([F(1,19)= 0.875, p= 0.4592], Figure 9B). Taken
together, the results show that deletion of the α5 gene has no significant overall effect on
ethanol consumption even in a wide range of concentrations.
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Figure 9. Deletion of the Chrna5 gene has no effect on two bottle choice drinking behavior in
C57BL/6J mice. Data (mean + SEM) represent (A) intake in g/kg and (B) preference ratio during 4
weeks of exposure to increasing concentrations ETOH. N= 11 per group.
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Intermittent Access
Mice given either intermittent or continuous two-bottle choice access to water and
increasing concentrations of ethanol during the acclimation week (Week 1) displayed a
concentration-dependent increase in ethanol intake (Figure 10).

An initial three-way

ANOVA (access group x concentration x genotype) revealed main significant effects of
access group [F(1,72)= 11.313, p< 0.0012, post-hoc =0.0002], and concentration [F(2,72)=
39.361, p< 0.0001, post-hoc =0.0001], but not genotype [F(1,72)= 0.533, p= 0.4678] nor
interaction [F(2,72)= 0.138, p= 0.8715].

Furthermore, the concentration-dependent

increase in ethanol intake was not due to differences in total fluid intake between groups as
three-way ANOVA analysis showed no difference between groups [F(2,63)= 0.249, p=
0.7807]. As for the preference results (Figure 11), three-way ANOVA revealed a main
significant effect of access group [F(1,72)= 5.552, p= 0.0212], but not concentration
[F(2,72)= 0.244, p= 0.7843], genotype [F(1,72)= 2.411, p= 0.1249] nor interaction [F(2,72)=
0.033, p= 0.9864].
For the maintenance phase of the experiment, weeks 2-4, intermittent access to ethanol
had the intended effect of increasing both intake and preference for ethanol in each test
group (Table 3). Two-way repeated-measures ANOVA analysis of ethanol intake revealed
a significant main effect of access group [F(1,18)= 49.479, p< 0.0001] but not genotype
[F(1,18)= 1.192. p= 0.2886] nor interaction [F(1,18)= 0.609, p= 0.4448] over the course of
the maintenance phase. Separate one-way repeated measures ANOVA analyses for each
week revealed significantly higher intake in intermittent access mice compared to
continuous access mice during week 2 [F(1,26)= 14.605, p= 0.007], week 3 [F(1,26)=
25.754, p< 0.0001], and week 4 [F(1,26)= 38.368, p< 0.0001]. The results for preference
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were similar with two-way repeated-measures ANOVA analysis revealing a significant main
effect of access group [F(1,18)= 28.156, p< 0.0001] but not genotype [F(1,18)= 0.959, p=
0.3405] nor interaction [F(1,18)= 0.350, p= 0.5614] over the course of the maintenance
phase (Table 3). Separate one-way repeated measures ANOVA analyses for each week
revealed significantly higher preference in intermittent access mice compared to
continuous access at mice during week 3 [F(1,23)= 13.524, p= 0.0012], and week 4
[F(1,26)= 9.545, p= 0.0047]. Taken together, the results show that intermittent exposure to
ethanol induces escalation of drinking behavior of a similar magnitude in both α5−/− and
α5+/+ mice.
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Figure 10. Deletion of the Chrna5 gene has no effect on intermittent access ethanol intake in
C57BL/6J mice. Data (mean + SEM) in the top graphs represent intake in g/kg in (A) WT and
(B) KO intermittent (IA) vs. continuous access (CA) groups at 3-, 6-, 10-, and 20% (w/v) ethanol
during weeks 1-5. The bottom graphs display the same data, but rearranged to show
comparisons between each genotype during (C) continuous and (D) intermittent access
exposure. N= 7 per group.
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Figure 11. Deletion of the Chrna5 gene has no effect on intermittent access ethanol preference
in C57BL/6J mice. Data (mean + SEM) in the top graphs represent the preference ratio in (A)
WT and (B) KO intermittent vs. continuous access groups at 3-, 6-, 10-, and 20% (w/v) ethanol
during weeks 1-5. The bottom graphs display the same data, but rearranged to show
comparisons between each genotype during (C) continuous and (D) intermittent access
exposure. N= 7 per group.

69

20% Ethanol Intake and Preference in Alpha 5 WT and KO mice
Treatment

CA

IA

Genotype

Alpha 5 WT

Alpha 5 KO

Alpha 5 WT

Alpha 5 KO

Intake
Weeks 2 -5

10.1 + 1.0

9.2 + 0.7

19.4 + 1.1 a

17.3 + 1.6a

Preference
Weeks 2-5

0.42 + 0.04

0.42 + 0.03

0.71 + 0.03a

0.67 + 0.06a

a

Represents significantly higher
intake or preference than CA

Table 1. Ethanol Intake and Preference in Alpha 5 WT and KO mice during the maintenance
phase of the IA procedure. Data (mean + SEM) represent intake in g/kg and preference ratio,
respectively, for each group.

70

DID

Finally, we assessed baseline ethanol consumption of the α5−/− and α5+/+ mice using the
DID paradigm.

As expected, α5+/+ mice displayed high intake during the 4-hr limited

access to ethanol for two days. However, there appeared to be no difference in DID intake
between untreated α5−/− and α5+/+ mice. Two-way repeated-measures ANOVA (genotype
x time) showed a significant effect of time [(F1,1)= 13.208, p= 0.0012], but not genotype
[(F1,27)= 0.191, p= 0.6653], nor interaction [(F1,1)= 0.2.868, p= 0.6653]. Thus, we show
that deletion of the α5 gene has no effect acute binge-drinking behavior in B6 mice during
period of forced access to ethanol. However, due to evidence that α5 gene deletion alters
nicotine self-administration behavior, we also evaluated the effect of nicotine on voluntary
ethanol consumption in α5−/− and α5+/+ mice using the DID procedure to determine if
effects of α5 gene deletion on DID would be detected in the presence of an agonist. As
intended, α5+/+ mice displayed high intake during the 4-hr limited access to ethanol, which
was attenuated by repeated nicotine treatments following a three day period of acclimation
injections with saline. Three way- repeated measures ANOVA (genotype x treatment x
time) showed a significant main effect of genotype [(F1,27)=4.239, p= 0.0346], treatment
[(F1,27)= 7.997, p= 0.0104], time [(F1,3)= 3.893, p= 0.0131], but not interaction [(F1,20)=
2.082, p= 0.1645]. Separate one-way ANOVA analyses for each day showed a significant
decrease in intake in nicotine-treated α5+/+ mice compared to saline control at Day 6
[(F1,10)= 9.265, p= 0.0124], Day 7 [(F1,10)= 8.205, p= 0.0168], Day 8 [(F1,10)= 4.685, p=
0.0557], and Day 9 [(F1,10)= 5.243, p= 0.0450]. One-way ANOVA analyses of nicotinetreated α5−/− mice, however, showed no sigfinicant difference in drinking behavior
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compared to saline control for neither Day 6 [(F1,10)= 4.706, p= 0.552], Day 7 [(F1,10)=
0.670, p= 0.4321], Day 8 [(F1,10)= .0019, p= 0.9754], nor Day 9 [(F1,10)= 0.526, p=
0.4851]. Interestingly, this was likely due to the fact that saline-pretreated α5−/− mice also
appeared to have reduced DID intake as compared to saline-pretreated α5 WT mice.
Indeed, separate one-way analyses for each day reveal a significant difference on Day 7
[(F1,10)= 5.518., p= 0.261] and Day 9, [(F1,10)= 7.723, p= 0.0195] indicating a reduction in
intake in saline-pretreated α5−/− mice compared to α5+/+ control for these days.
Furthermore, this reduction in drinking behavior did not occur in α5+/+ as intake during
baseline and the first two test days remained stable. A one-way ANOVA analysis showed
no siginificant difference in α5 WT mice on Day 6 [(F1,10)= 0.522, p= 0.4761] nor Day 7
[(F1,10)= 0.188, p= 0.6745] compared to baseline intake on Day 1 and Day 2. Thus, the
possible effect of nicotine on DID drinking behavior in α5−/− mice, if any, was obscured by
similar reduction in saline-pretreated α5−/− mice, which was perhaps induced by injection
stress experienced by the α5−/− mice.
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Figure 12. Deletion of the Chrna5 gene reduces DID drinking behavior after repeated
injections of saline or nicotine in C57BL/6J mice. Data (mean + SEM) represent daily
DID ethanol intake in g/kg for 4 hours in α5−/− and α5+/+ mice during (A) baseline
drinking before injections on days 1 and 2, and (B) drinking after injections of saline or
nicotine on Days 6-9 in C57BL/6J mice. Graph (C) shows the same data for days 6-9
but with the nicotine groups removed. N= 6-15 per group.
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3.4

Summary
The goal of these studies was to assess the potential influence of the α5 nAChR-

coding gene on ethanol-responsive behaviors in an in vivo animal model. We examined
mice in a battery of tests for acute ethanol-responsive behaviors, including hypothermia,
LORR, reduction of anxiety-like behavior in EPM, and reward-like effects in CPP, as
well as in chronic drinking behavior in the two-bottle choice model. Because there are
no currently available ligands selective for α5* nAChRs, we examined the effects of α5
gene deletion on these behavioral effects in ethanol preferring C57 mice. Our results
showed that these mice consistently displayed an enhanced response to hypothermia,
LORR, and anxiolysis behavior in the EPM following acute ethanol challenge. We also
found, in contrast, that CPP behavior conditioned by repeated ethanol injections was
reduced when the mice were observed on test day in a drug free state. Surprisingly,
these effects did not translate into changes in ethanol drinking behavior as measured by
the two-bottle choice, intermittent access drinking and DID drinking paradigms was
altered only after repeated injections with either saline or nicotine.
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CHAPTER 4: CHARACTERIZATION OF α4β2*
α4β2 NICOTINIC ACETYLCHOLINE
RECEPTORS IN ETHANOL-RESPONSIVE BEHAVIORS

4.1

Introduction
Alcohol (ethanol) and nicotine addiction are two of the leading causes of preventable

death worldwide. In the United States alone, it is estimated that up to 7% of the entire
population is co-dependent upon these substances (Burns & Proctor, 2013; Anthony &
Echeagaray-Wagner, 2000; Istvan & Matarazzo, 1984). Studies also show that alcohol
dependence is three times more common among smokers than non-smokers and this high
co-morbidity of use increases the difficulty of achieving long-term abstinence with either
drug (Larsson et al. 2004a, Grucza et al. 2006). Furthermore, there is a high genetic
correlation between alcohol and nicotine dependent individuals suggesting common
neurobiological mechanisms mediating co-abuse (True et al.1999; Davis & de Fiebre
2006). Nicotinic acetylcholine receptors (nAChRs) may be prime candidates for mediating
this vulnerability to alcoholism and nicotine addiction.
Neuronal nAChRs are ligands-gated ion channels consisting of five transmembrane
spanning proteins, or subunits. These subunits complex to form many combinations of
nAChR subtype consisting of α (α2−α10) and/or β (β2−β4) subunits.

β2* nAChRs (*

denotes the presence of additional nicotinic subunits) represent the most widely distributed
and best-characterized nAChR subtypes to date (Gotti et al 2007; Changeux 2009 and
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2010). Furthermore, this receptor subtype plays a critical role in nicotine dependence
(Picciotto et al. 1998).

For example, nicotine self-administration is reduced in rats

pretreated with dihydro-β-erythroidine (DHβE), an antagonist selective for β2*-containing
subtypes (Cohen et al.2008).

The β2* subtype also plays a major role in nicotine

reinforcement (Picciotto et al. 1998), nicotine conditioned place preference (Walters et al.,
2006) and drug discrimination in rats and mice (Shoaib et al. 2002, Smith et al. 2007).
Therefore, studies on the role of the β2* nAChRs in alcohol phenotypes

continue to

emerge. For example, β2 genetic Knockout (KO) mice are less sensitive to both ethanol’s
acute effects in the acoustic startle response and to ethanol withdrawal signs compared
with β2 wild-type (WT) mice (Owens et al. 2003, Butt et al. 2004).

Interestingly, the

impairment of contextual recall by ethanol was not affected in β2* KO mice (Wehner et al.
2004). In addition to the previously mentioned effects, full agonists such as nicotine and
RJR-2403 decreased ethanol-induced ataxia while a partial agonist. Varenicline, a nonselective α4β2* nAChRs partial agonist, actually increases the sensitivity to this response
(Taslim et al. 2007, 2010; Kamens et al. 2010). Varenicline also increases sensitivity to the
sedative-hypnotic effects of acute ethanol as tested in the rotorod and Loss of Righting
Response assays (Kamens et al. 2010).
In contrast to the acute administration studies previously mentioned, no changes in
chronic ethanol drinking behavior in the two-bottle choice paradigm were found in the β2
KO mice compared to their WT counterparts (Kamens et al. 2010). DHβE also had no
effect on either ethanol consumption (Hendrickson et al. 2009; Kuzmin et al. 2009) nor
dopamine release in the ventral tegmental area or nucleus accumbens in response to
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ethanol-associated cues (Ericson et al. 2003, 2008, Larsson et al. 2004a,b). Interestingly,
a polymorphism in the β2 gene (CHRNB2) has also been associated with the initial
subjective response to alcohol in human subjects (Ehringer et al. 2007). Collectively these
studies suggest that β2* nAChRs may be important for modulating ethanol-responsive
behavior, particularly the pharmacological effects after acute exposure to the drug. The
initial sensitivity of an individual to the acute effects of early alcohol exposure is becoming
an increasingly attractive endophenotype for alcoholism vulnerability.

A 25-year study

conducted by Schuckit and colleagues (2011) showed that the level of response to acute
alcohol exposure early in life was predictive of future drinking behavior and alcohol abuse
liability.
The aim of these studies was to more fully characterize the role of β2* nAChRs in
ethanol-responsive behaviors in mice after acute exposure to the drug. To do this, we
tested mice lacking Chrnb2 or pretreated with a selective β2* nAChRs antagonist for a
range of ethanol-induced behaviors, namely locomotor depression, hypothermia, hypnosis,
and anxiolysis. We also tested the effect of activation of β2* nAChRs on these ethanolinduced behaviors through the use of the partial agonists, varenicline and sazetidine-A, as
well as the full agonist, nicotine. Finally, , we tested mice lacking Chrnb2 for voluntary
ethanol consumption using an intermittent access two-bottle choice alcohol paradigm since
these mice have not previously been tested in this model of ethanol consumption.
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4.2

Methods

Animals
Male C57BL/6J mice were purchased from Jackson laboratories (Bar Harbor, ME). β2-/mice; (Institut Pasteur, Paris, France) and their wild-type β2+/+ littermates were bred in an
animal care facility at Virginia Commonwealth University.

All the mice used in each

experiment were backcrossed at least 10 to 12 generations. Mutant and wild types were
obtained from crossing heterozygote (β2+/- ) mice. This breeding scheme controlled for any
irregularities that might occur with crossing solely mutant animals. Mice were housed in a
21°C humidity-controlled Association for Assessment and Accreditation of Laboratory
Animal Care (AALAC)-approved animal care facility. They were housed in groups of six
and had free access to food and water under a 12-h light/dark cycle (lights on at 6:00 a.m.)
schedule. Mice were 8–10 weeks of age and weighed approximately 20–25 g at the start of
all the experiments.

All experiments were performed during the normal light cycle

(between 6:00 a.m. and 6:00 p.m.) and the study was approved by the Institutional Animal
Care and Use Committee of Virginia Commonwealth University. All studies were carried
out in accordance with the National Institute of Health guide for the Care and Use of
Laboratory animals.

Drugs
Dihydro-β-erythroidine (DHβE) was purchased from Sigma- RBI (Natick, MA, USA). (-)Nicotine hydrogen tartrate salt was purchased from Sigma-Aldrich (St. Louis, MO).
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Varenicline [7,8,9,10-tetrahydro- 6,10-methano- 6H-pyrazino (2,3-h)(3) benzazepine] and
sazetidine-A [6-[5-[(2S)-2-azetidinylmethoxy]-3-pyridinyl]- 5-hexyn-1-ol] were supplied by
the National Institute of Drug Abuse Drug Supply Program (Bethesda, MD). DHβE doses
(1.0- and 3.0 mg/kg) were based on published and unpublished studies from our lab that
were within an effective range of doses for blocking the behavioral effects of nicotine
(Damaj et al. 1995, 2003). Varenicline doses (0.10 - 4.0 mg/kg) and Sazetidine A doses
(1.0mg/kg) were based on previous studies that were within an effective range of doses for
blocking the behavioral effects of ethanol (Kamens et al. 2010b,Rezvani et al.2010).
Nicotine doses (0.1 – 0.5 mg/kg) were chosen based on an effective range of doses
behavioral active for CPP preference and self-administration (Walters et al 2005).

All

drugs were dissolved in 0.9% saline and injected intraperitoneally (i.p.), except nicotine,
which was delivered subcutaneously (s.c.), at a volume of 10 ml/kg body weight. Ethanol
was also dissolved in 0.9% saline and prepared as a 20% (v/v) solution which were
delivered via i.p. injection for acute experiments or per os (p.o.) for drinking experiments.
Ethanol doses (2.0 – 3.5 g/kg) were chosen based on effective doses obtained in dose
response curves conducted before each study, which were consistent with those found in
literature (Alanka et al. 1992, Browman et al.2000).

Locomotor Activity Measurement
Locomotor depression induced by acute ethanol was assessed in Omnitech photocell
activity cages (28 x 16.5 cm) (Columbus, OH). Each apparatus consisted of two banks of
eight cells with locomotor activity recorded as the interruptions of the photocell beams for
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the duration of the test. Mice were allowed to acclimate to the room at least 1 hr before the
beginning of the procedure. Animals were injected with saline on days 1 and 2, and then
injected with 2.5 g/kg ethanol (i.p.) on day 3 after receiving a 10 min pretreatment with
DHβE or saline (i.p.). For experiments with β2-/- and β2+/+ mice, subjects were injected with
saline on days 1 and 2, and then directly treated with either ethanol (2.5 g/kg) or saline
alone on day 3. Locomotor activity scores were defined as the number of interruptions of
the photobeam cells measured for 10 minutes. Data were expressed as mean ± SEM of
the number of photocell interruptions.
Measurement of Hypothermia, LORR, EPM
We used a similar protocols, respectively, as previously described in Chapter 3
Intermittent Access
Chronic ethanol drinking behavior was assessed using the intermittent access (IA)
procedure as described by Hwa and colleagues (Hwa et al. 2011). This procedure is
advantageous over the traditional two-bottle choice drinking procedure in that it produces
escalation in ethanol drinking by repeated deprivation cycles thus better approximating
human drinking behavior (Rodd et al. 2004). Briefly, β2-/- and β2+/+ mice were housed
individually in cages one week prior to testing with ad libitum access to food and water.
Three days before the end of acclimation week, water bottles were replaced with two
drinking tubes, made from 10-ml serological pipettes containing a double bearing sipper
tube and a rubber stopper on either end of the tube, filled with water. At the end of the
acclimation period, one water tube was replaced with one ethanol filled with 3-, 6-, and
10% w/v ethanol on alternating days (Sunday, Tuesday, and Thursday) while two water
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tubes were presented on the deprivation days (Monday, Wednesday, Friday, and
Saturday). After one week, 20% (w/v) ethanol tubes were presented on alternating days
(Sunday, Tuesday, and Thursday) for the remainder of the experiment. Control mice were
presented with continuous access to ethanol by presenting one 3% (w/v) ethanol tube on
Sunday and Monday, 6% Tuesday and Wednesday, and 10% (w/v) ethanol Thursday,
Friday, and Saturday. After one week, 20% (w/v) ethanol tubes were presented daily for
the remainder of the experiment. Additionally, ethanol and water tubes were placed on two
empty cages which allowed for measurement of leakage and evaporation from the tubes.
The average volume depleted from these “control” tubes was subtracted from the individual
drinking volumes each day before data analysis. Intake was reported as g/kg ethanol
consumed and preference as the ratio between of ethanol consumed divided by total
amount of ethanol and water fluid intake (ml), combined.

Additional measurements

including body weight (g) and total fluid intake (ml) were also recorded. Data (mean ±
SEM) were expressed as total intake or preference ratio.

Statistical Analysis
Data were analyzed using multiple standard analyses of variance (ANOVA) with treatment,
dose, and/or genotype as independent variables. All analyses were followed by Bonferroni
post-hoc tests where appropriate to further analyze significant data with the null hypothesis
rejected at the 0.05 level. For the IA procedure, ethanol intake (g ⁄ kg), body weight (g),
volume of ethanol intake (ml), water intake (ml), total fluid intake (ml), and ethanol
preference ratio during the week of increasing ethanol concentrations (week 1) for each
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access group and genotype were analyzed with multiple three-way analyses of variance
(ANOVAs), followed by Bonferroni post hoc analysis when significant group effects were
found (p < 0.05). During the maintenance phase with 20% ethanol (weeks 2-5), ethanol
intake (g ⁄ kg), body weight (g), volume of ethanol intake (ml), water intake (ml), total fluid
intake (ml), and ethanol preference ratio were analyzed between each treatment and
genotype with multiple two-way repeated measures ANOVAs followed by Bonferroni post
hoc analysis when significant group effects were found (p < 0.05).

4.3

Results

Locomotor Activity Measurement
We tested locomotor activity 10 min after 2.5 g/kg ethanol injection (i.p.) since this is
sufficient time for blood and brain ethanol concentrations to reach equilibrium (Smolen
& Smolen, 1989).

Mice treated with ethanol displayed a significant decrease in

locomotor activity (Figure 14A).

One-way ANOVA analysis showed that ethanol

produced a significant decrease in locomotor activity compared with findings for control
animals [(F3,20)= 6.821, p=0.0024]. There was no effect of 3.0 mg/kg DHβE treatment
on this ethanol-induced depression [(F1,10)= 3.47, p= 0.0919]. Similarly, absence of
the β2 gene in KO mice did not modulate locomotor depression induced by an acute
injection of 2.5 g/kg ethanol (i.p.) (Figure 14B). A two-way ANOVA analysis showed a
significant main effect of ethanol treatment [(F1,19) = 56.85, p<0.0001] but not genotype
[(F1,19)= 0.019, p= 0.8913] nor interaction [(F1,19)= 3.20, p= 0.08] on locomotor
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activity. Thus, the analysis suggests that neither the β2* antagonist, DHβE, nor Chrnb2
deletion affects acute ethanol-induced locomotor depression in mice.
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Figure 13. Effects of DHβE pretreatment and deletion of the Chrnb2 gene on ethanol-induced
locomotor depression in mice.

Data (mean + SEM) represent total number of photocell

interruptions of (A) C57BL/6J mice with 10 min DHβE pretreatment and (B) β2-/- mice after
receiving an injection of 2.5 g/kg ethanol or saline. N= 6 per group.
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Body Temperature Measurement
Treatment with 3.0 g/kg ethanol (i.p.) induced a significant drop in body temperature
(Figure 15A). Two-way repeated measures ANOVA (treatment x time) revealed ethanol
treatment caused significant hypothermia compared to saline control animals [F(3,18)=
17.359; p< 0.0001] at 15- and 60-min time points post ethanol injection. A dose of 3.0
mg/kg DHβE treatment did not produce significant changes [F (1,10)= 0.991; p= 0.3430]
in ethanol-induced hypothermia compared to findings with control animals indicating this
dose of DHβE has no effect on this measure of acute ethanol-responsive behavior.
Deletion of the β2 gene also had no effect on hypothermia induced by an acute injection
of 3.0 g/kg ethanol (i.p.) (Figure 15B). Three-way repeated measure ANOVA (genotype
x treatment group x time) showed a main significant effect of ethanol treatment
[F(1,20)= 0.126, p< 0.0001), but neither genotype [F(1,20)= 1.844, p< 0.1897] nor
interaction [F(1,20)= 0.1897, p< 0.7263] on change in body temperature . There were
also no genotype differences detected between saline control groups. Taken together,
these results suggest that pharmacological and genetic antagonism of β2* nAChRs
have no effect on acute ethanol-induced hypothermia.
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Figure 14. Effects of DHβE pretreatment and deletion of the Chrnb2 gene have no effect on
ethanol-induced hypothermia in C57BL/6J mice. Data (mean + SEM) represent the change in
body temperature from baseline in degrees Celsius of (A) mice with 10 min DHβE pretreatment
and (B) β2-/- mice at 15- and 60 min time points after receiving an injection of 3.0 g/kg ethanol. N=
6 per group.
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LORR
A dose of 3.5 g/kg ethanol had the intended effect of inducing LORR (Figure 16). A
one-way ANOVA analysis revealed that while there was no significant effect of either
1.0- or 3.0 mg/kg DHβE treatment on latency to LORR onset ([F(3,35)= 0.456; p=
0.7144], Figure 16A), the nicotinic antagonist significantly reduced LORR duration at
these doses ([F(1,20)= 6.982; p= 0.0156], Figure 16B). β2-/- mice showed a similar
response (Figure 17) with one-way ANOVA analysis showing genotype did not have an
effect on the latency to LORR onset ([F(1,13)= 0.92; p= 0.7669], Figure 17A) but did
have a significant effect on LORR duration ([F(1,13)= 5.57; p= 0.346] between KO and
WT mice (Figure 17B). β2-/- mice took less time to right themselves than β2+/+ mice,
thus displaying decreased response to the hypnotic effects induced by acute ethanol.
These results show that pharmacological and genetic antagonism of β2* nAChRs
reduces the response to ethanol-induced hypnosis in naïve mice.

Conversely, testing with the partial agonists varenicline and sazetidine-A, and the full
agonist, nicotine, produced similar results for LORR onset, but produced opposite
results for LORR duration (Figures 18-20). One-way ANOVA analysis revealed no
significant effects of sazetidine-A ([F(2,17)= 1.059.; p= 0.3686, Figure 19A), and a
marginal but non-significant dose-dependent effect of both varenicline at 1.0 and 4.0
mg/kg ([F(2,18)= 3.747; p= 0.0536], Figure 18A) and nicotine at 0.1- and 0.5 mg/kg
([F(2,10)= 1.724; p= 0.2274, Figure 20A) on latency to LORR onset compared to saline
control. However, one-way ANOVA showed a significant dose-dependent
enhancement of LORR duration in subjects treated with varenicline at 1.0 and 4.0
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mg/kg ([F(2,18)= 7.510; p= 0.0042], Figure 18B), sazetidine-A at 1.0- and 3.0 mg/kg
([F(2,17)= 9.463; p= 0.0017], Figure 19B), and nicotine at 0.1- and 0.5 mg/kg ([F(2,10)=
5.300; p= 0.0270], Figure 20B) compared to saline control. Taken together, it appears
evident that activation of nAChRs, by either partial or full agonists consistently
enhances the time to recover from ethanol-induced LORR, while differentially affecting
LORR onset depending on each drugs affinity for certain nAChR subtypes.
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Fi
Figure 15. DHβE pretreatment reduces ethanol-induced LORR duration while having no effect on
LORR onset in C57BL/6J mice. Data (mean + SEM) represent (A) latency to LORR onset and (B)
total duration of LORR in seconds in mice with 10 min DHβE pretreatment after receiving an
injection of 3.5 g/kg ethanol. N= 7-10 per group.
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Figure 16. Deletion of the Chrnb2 gene reduces ethanol-induced LORR duration while having
no effect on LORR onset in C57BL/6J mice. Data (mean + SEM) represent (A) latency to
LORR onset and (B) total duration of LORR in seconds in β2-/- and β2+/+ mice after receiving an
injection of 3.5 g/kg ethanol. N= 7-10 per group.
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Figure 17.

Varenicline pretreatment dose-dependently enhances LORR duration with a

tendency to reduce LORR onset time in C57BL/6J mice. Data (mean + SEM) represent (A)
latency to LORR onset and (B) total duration of LORR in varenicline pretreated mice in seconds
after receiving an injection of 3.5 g/kg ethanol. N= 7-10 per group.
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Figure 18. Sazetidine-A pretreatment dose-dependently enhances LORR duration while having
no effect on LORR onset in C57BL/6J mice. Data (mean + SEM) represent (A) latency to
LORR onset and (B) total duration of LORR in Sazetidine A pretreated mice in seconds after
receiving an injection of 3.5 g/kg ethanol. N= 7-10 per group.
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Figure 19. Nicotine pretreatment dose-dependently enhances LORR duration with a tendency
to reduce LORR onset time in C57BL/6J mice. Data (mean + SEM) represent (A) latency to
LORR onset and (B) total duration of LORR in nicotine pretreated mice in seconds after
receiving an injection of 3.5 g/kg ethanol. N= 7-10 per group.
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EPM
As expected, a dose of 2.0 g/kg ethanol caused an anxiolytic-like response in mice
compared with saline-treated mice without effecting locomotor activity (Figure 21). Twoway ANOVA analysis showed a main significant of ethanol treatment [F(1,17)= 24.795; p=
0.0001] as well as interaction between ethanol and DHβE pretreatment [F(1,17)= 7.669; p=
0.0131, post-hoc p< 0.05] but not DHβE pretreatment alone (Figure 21A).

One-way

ANOVA analysis of the number of crossovers revealed no significant differences between
either group [F(3,18)= 2.16; p= 0.1011] (Figure 21B). The results in β2−/− mice showed that
ethanol-induced increase in open arm time was also enhanced in these mice compared to
WT (Figure 21A). Two-way ANOVA analysis of time spent in the open arms showed a
significant main effect of treatment [F(1,17)= 33.711; p<.0001], genotype [F(1,17)= 7.38; p=
0.0147], and interaction [F(1,17)= 7.116; p= 0.0162].

Subsequent one-way ANOVA

analysis revealed a significant difference in ethanol-treated KO mice [F (1,10)= 5.521, p<
0.0407, post-hoc p< 0.05] compared to WT mice. No differences were detected in either
genotype treated with saline.

One-way ANOVA analysis of the number of crossovers

revealed no significant differences between either group ([F (1,17)= 2.729, p< 0.1169],
Figure 21B). To confirm if this effect was mediated through β2 nAChRs we also tested the
effect of DHβE pretreatment in β2 KO and WT mice. One-way ANOVA analysis revealed a
trend for a KO-pretreated mice to spend less time in the open arms than their WT
counterparts, though this trend was non-significant [F(1,10)= 2.770; p= 0.1270].
Furthermore, One-way ANOVA analysis was also used to compare DHβE-pretreated WT
mice to WT mice from the previous experiment treated with ethanol alone, revealing that
DHβE-pretreated WT mice did indeed spend more time in the open arms than the control
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[F(1,11)= 5.084 ; p=0.0455 ]. Thus, the data reveal that DHβE significantly increased
ethanol-induced open arm in β2+/+ but not β2-/- mice. Taken together, these data suggest
that functional disruption of β2* nAChRs enhances aspects of the anxiety-reducing effects
of acute ethanol administration as measured by the EPM.
Treatment with the partial agonists, by contrast, caused a decrease in ethanol-induced
open arm time in drug treated mice. However, it appears that this effect was due changes
in locomotor activity (Figures 22 and 23).

Two-way ANOVA analysis showed a main

significant effect of ethanol treatment [F(1,17)= 6.078; p= 0.0354] as well as interaction
between ethanol and varenicline pretreatment [F(1,17)= 5.136; p= 0.0431, post-hoc p<
0.05] but not pretreatment (Figure 22A). Subsequent one-way ANOVA analysis of the
ethanol treatment groups revealed a significant difference in varenicline pretreated mice [F
(1,8)= 5.641, p< 0.0467, post-hoc p< 0.05] compared to saline pretreated mice. However,
this difference seemed to be a caused by significant decline in locomotor activity as oneway ANOVA analysis of the number of crossovers across these groups revealed a
significant difference between varenicline pretreated mice [F(1,8)= 2.16; p= 0.1011] and
saline control (Figure 22B).

Similar behavior was observed in sazetidine-A pretreated

mice. Two-way ANOVA analysis revealed a main significant effect of ethanol treatment
[F(1,11)= 6.978; p= 0.0354] as well as interaction between ethanol and varenicline
pretreatment [F(1,11)= 5.136; p= 0.0431, post-hoc p< 0.05] (Figure 23A), but one-way
ANOVA showed a significant decreased in number of crossovers in sazetidine-A and saline
pretreated ethanol treatment groups ([F(1,5)= 2.16; p= 0.1011], Figure 23B). Thus, little
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conclusion can be drawn from these results due to the locomotor effects of varenicline and
sazetidine-A in combination with ethanol in this particular assay.
Interestingly, treatment with full agonist, nicotine, however, produced similar effects on
ethanol-induced reduction in open arm time compared to DHβE-treated and β2 KO mice
(Figure 24).

Two-way ANOVA analysis of time spent in the open arms showed a

significant main effect of ethanol treatment [F(1,17)= 6.988; p<0.0312] and interaction
[F(1,17)= 8.116; p= 0.0262], but not nicotine pretreatment [F(1,17)= 7.38; p= 0.0147].
Subsequent one-way ANOVA analysis revealed a significant difference in nicotine
pretreated [F(1,8)= 5.821, p< 0.0497, post-hoc p< 0.05] and saline-pretreated ethanol
groups (Figure 24A).

Furthermore.

This effect was not due to changes in locomotor

activity since one-way ANOVA analysis of the number of crossovers revealed no significant
differences between either group ([F (1,8)= 2.827, p< 0.1384], Figure 24B).

Taken

together, it appears evident that activation of β2* nAChRs and potentially other subtypes
targeted by nicotine, enhances anxiolytic-like activity induced by ethanol in a manner
similar to antagonism of β2* nAChRs by pharmacological antagonist or gene deletion.
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Figure 20. Deletion of the Chrnb2 gene enhances ethanol-induced increase in open arm time
and attenuates DHβE’s effect on this behavior without affecting locomotor activity. Data (mean +
SEM) represent (A) time spent in open arms in seconds and (B) total number of crossovers in β2
KO mice after receiving an injection of 2.0 g/kg ethanol. N= 7 per group.
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Figure 21. Varenicline pretreatment reduces ethanol-induced increase in open arm time and
locomotor activity in C57BL/6J mice. Data (mean + SEM) represent (A) time spent in open arms in
seconds and (B) total number of crossovers in varenicline-pretreated mice after receiving an
injection of 2.0 g/kg ethanol. N= 6-7 per group
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Figure 22. Sazetidine-A pretreatment reduces ethanol-induced increase in open arm time and
locomotor activity in C57BL/6J mice. Data (mean + SEM) represent (A) time spent in open arms in
seconds and (B) total number of crossovers in sazetidine-A-pretreated mice after receiving an
injection of 2.0 g/kg ethanol. N= 6-7 per group
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Figure 23.

Nicotine enhances ethanol-induced increase in open arm time without affecting

locomotor activity in C57BL/J Mice. Data (mean + SEM) represent (A) time spent in open arms in
seconds and (B) total number of crossovers in nicotine-pretreated mice after receiving an injection
of 2.0 g/kg ethanol. N= 7-11 per group.

100

Intermittent Access
Mice given either intermittent or continuous two-bottle choice access to water and
increasing concentrations of ethanol during the acclimation week (Week 1) displayed a
concentration-dependent increase in ethanol intake (Figure 25).

An initial three-way

ANOVA (access group x concentration x genotype) revealed main significant effects of
concentration [F(2,63)=130.457, p= 0.0001, post-hoc =0.0001], genotype [F(1,63)= 5.317 ,
p= 0.0244, post-hoc< 0.05], and interaction [F(1,63)= 7.892, p= 0.0066]. Separate oneway ANOVA analyses for KO and WT mice at each concentration showed that while WT
mice with continuous or intermittent access displayed similar ethanol intake, KO mice with
continuous access had significantly higher intake at 6% ethanol [F(1,10)= 6.011, p= 0.034]
than their counterparts with intermittent access.

Thus, the data show that while the

increase in ethanol intake during the first week was driven largely by concentration,
genotype did modestly influence ethanol depending on access conditions. Furthermore,
the concentration-dependent increase in ethanol intake was not due to differences in total
fluid intake between groups as three-way ANOVA analysis showed no difference between
groups [F(2,63)= 0.249, p= 0.7807]. As for the preference results (Figure 26), three-way
ANOVA revealed a main significant effect of access group [F(1,63)= 4.678, p= 0.0344] and
access group x genotype interaction [F(1,63)= 6.750, p= 0.0117] with further analysis
supporting the effect of access group (post hoc, p= 0.05) but not genotype (post hoc, p>
0.05) on ethanol preference for 3% ethanol ([F(1,10)= 8.722, p= 0.0145]. Thus, while this
effect on preference did not depend on concentration or genotype, it seemed that the
conditions of access to ethanol, either intermittent or continuous, did initially affect
preference for ethanol in drug naïve mice.
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For the maintenance phase of the experiment, weeks 2-5, intermittent access to ethanol
had the intended effect of increasing both intake and preference for ethanol in each test
group (Table 2). Two-way repeated-measures ANOVA analysis of ethanol intake revealed
a significant main effect of access group [F(1,16)= 18.65, p= 0.0005] but not genotype
[F(1,16)= , p= 0.0687] nor interaction [F(1,16)= 0.206, p= 0.6557] over the course of the
maintenance phase. Separate one-way repeated measures ANOVA analyses for each
week revealed significantly higher intake in intermittent access mice compared to
continuous access mice during week 3 [F(1,23)= 5.653., p= 0.261], week 4 [F(1,23)=
26.718, p< 0.0001], and week 5 [F(1,23)= 20.139, p= 0.0002]. The results for preference
were similar with two-way repeated-measures ANOVA analysis revealing a significant main
effect of access group [F(1,17)= 20.361 p= 0.0003] but not genotype [F(1,17)= 0.732 p=
0.732] nor interaction [F(1,17)= 0.002, p= 0.9661] over the course of the maintenance
phase (Table 2). Separate one-way repeated measures ANOVA analyses for each week
revealed significantly higher preference in intermittent access mice compared to
continuous access at mice during week 4 [F(1,23)= 15.006, p= 0.0007], and week 5
[F(1,23)= 20.445, p= 0.0002]. Taken together, the results show that intermittent exposure
to ethanol induces escalation of drinking behavior of a similar magnitude in both β2-/- and
β2+/+ mice.
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Figure 24. Deletion of the Chrnb2 gene has no effect on intermittent access ethanol intake in
C57BL/6J mice. Data (mean + SEM) in the top graphs represent intake in g/kg in (A) WT and (B)
KO intermittent (IA) vs. continuous access (CA) groups at 3-, 6-, 10-, and 20% (w/v) ethanol during
weeks 1-5. The bottom graphs display the same data, but rearranged to show comparisons
between each genotype during (C) continuous and (D) intermittent access exposure. N= 7 per
group.
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Figure 25. Deletion of the Chrnb2 gene has no effect on intermittent access ethanol preference in
C57BL/6J mice. Data (mean + SEM) in the top graphs represent the preference ratio in (A) WT
and (B) KO intermittent vs. continuous access groups at 3-, 6-, 10-, and 20% (w/v) ethanol during
weeks 1-5. The bottom graphs display the same data, but rearranged to show comparisons
between each genotype during (C) continuous and (D) intermittent access exposure. N= 7 per
group.
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20% Ethanol Intake and Preference in Beta 2 WT and KO mice
Treatment

CA

IA

Genotype

Beta 2 WT

Beta 2 KO

Beta 2 WT

Beta 2 KO

Intake
Weeks 2 -5

12.35 + 1.80

14.59 + 1.55

16.73 + 1.48a

20.20 + 1.26a

Preference
Weeks 2-5

0.46 + 0.04

0.48 + 0.04

0.64 + 0.05

a

0.68 + 0.05

a

a

Represents significantly higher
intake or preference than CA

Table 2. Ethanol Intake and Preference in Beta 2 WT and KO mice during the maintenance phase
of the IA procedure.

Data (mean + SEM) represent intake in g/kg and preference ratio,

respectively, for each group.
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4.4

Summary

The goal of our studies was to further characterize the involvement of β2* nAChRs in acute
ethanol-responsive behaviors as well as in ethanol drinking behavior. We examined the
effect of pharmacological antagonism and genetic deletion of β2* nAChRs on a wide range
of acute responses including locomotor depression, hypothermia, LORR, and reduction of
anxiety-like behavior in the EPM, as well as in escalated drinking behavior using an
intermittent access model.

As hypothesized, manipulation of β2* nAChRs modulated

some acute behaviors, namely reducing LORR duration and increasing time spent in the
open arms in the EPM, while having minimal effect on ethanol drinking behavior.
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CHAPTER 5: GENERAL DISCUSSION

We undertook the preceding studies in order to determine the contribution of
certain nicotinic acetylcholine receptors (nAChRs) to dependence–related alcohol
behaviors in the mouse. Specifically, we set out to more fully characterize the role of
α5* nAChRs, a subtype whose respective gene has been identified in a number of
recent studies as being associated with some phenotypes that characterize alcohol
dependence. Furthermore, because α5* nAChRs cannot exist without the presence of
at least one other α and β subunit, we also examined the α4β2* nAChR, a subtype with
which the α5 subunit is commonly co-expressed and has also been shown to modulate
some ethanol-responsive behaviors. The examination of α5* and α4β2* subtypes was
also beneficial since each are shown to be important mediators of the effects of
nicotine, a drug commonly co-abused with alcohol
Overall, we demonstrated that reduced receptor function by α5 gene deletion
conferred enhanced sensitivity to the acute behavioral effects induced by acute ethanol.
Specifically, α5−/− mice showed an increased hypothermic response to ethanol, took
longer to fully recover from ethanol’s hypnotic effects in the Loss of Righting Reflex
(LORR) assay, and spent more time in the open arms in the elevated plus maze (EPM)
than WT mice indicating increased sensitivity to the anxiolytic-like behavioral effects of
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acute ethanol. In contrast, α5 gene deletion blunted the response to ethanol’s rewardlike effects in the CPP paradigm.

Furthermore, none of these effects were due to

pharmacokinetic differences between genotypes as α5−/− and WT mice displayed
similar blood ethanol concentrations (BEC) over a 2-hr time course after injection with
ethanol.
We chose to test the behaviors listed due to their ability to give us an idea of
specific brain pathways, and thus possibly the mechanisms involved in mediating
sensitivity to ethanol-induced phenotypes. Our results with hypothermia showed that
removal of the α5 gene resulted in general increase in body temperature change
induced by ethanol, indicating that α5 nAChRs in the hypothalamus may have some
role in regulating this response to alcohol. Though the exact molecular mechanisms
underlying thermoregulation by the hypothalamus is mammal is unknown, this brain
region is part of the hypothalamic-pituitary adrenal (HPA) axis which could have some
important implications for stress-related drinking behavior. A particularly noteworthy
observation was a significant difference in hypothermia in WT and KO mice was found
at the 60 min, but not 15-min time point following ethanol administration. Furthermore,
WT mice tended to display a slight decrease in hypothermia, while KO mice tended to
display the opposite, thus giving the appearance of enhanced sensitivity. Future studies
should include an extended time course, (e.g. up to 240 min) to determine the extent of
this effect.
Interestingly, our results seem to be in line with recent human genetic studies
regarding the α5 gene. For example, genome wide association studies (GWA) studies
identified two single nucleotide polymorphisms (SNPs) in the α5 nAChR-coding gene
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that were associated with changes in body sway, a measure of sensitivity to the ataxic
effects produced in a subject challenged with acute alcohol (Joslyn et al. 2008). These
same SNPs were associated with measures of subjective response to acute alcohol
challenge, while an additional set of SNPs were identified as being associated with the
age of initiation for alcohol use (Schlaepfer et al. 2008b). Furthermore, associations
were also identified between polymorphisms in the α5 gene with alcohol dependence
phenotypes and steady state mRNA levels (Wang et al. 2009).
Another striking observation made in these studies was that α5 gene deletion
had the opposite effect on acute behavioral response to ethanol when compared to
nicotine studies in literature. While our data demonstrate an enhanced response to the
hypothermic and sedative effects of ethanol, previous literature investigating the effects
of α5 gene deletion on nicotine response show that these mice have a diminished
response to the hypothermic and sedative effects of ethanol (Jackson et al. 2010).
Moreover, it was also shown that α5 gene deletion led to an increase in nicotine’s
reward-like effects in CPP and intake (Jackson et al. 2010), which we, again, showed is
opposite in the case of ethanol. These observations that acute behavioral response to
both ethanol and nicotine can be modulated oppositely by deletion of the same gene
provides more evidence in support of a link between α5* nAChRs and dependence to
these drugs. GWA studies of the genomic region encoding for α5* nAChRs in humans
showed the risk variant associated with nicotine dependence bears the opposite alleles
of the variant associated with alcohol dependence risk (Chen et al. 2009). Interestingly,
this variant is known to significantly decrease the maximal response of α5* nAChRs to
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agonists by up to 50%, which indicates that change in the functional properties of this
subtype could play a role in drug dependence (Bierut et al. 2008, Kuryatov et al. 2011).
Thus, the behavioral data generated by our studies and others corroborate the GWA
studies in humans, even if modestly.

However, we make such interpretations with

caution. As previously explained, there may have been developmental compensation
events that occurred with deletion of the α5 gene that could have influenced the
behaviors we observed. We believe that our interpretations are strengthened by the
fact that expression of many nAChR subunits are not altered by removal of the α5 gene
(Mao et al. 2008, Kuyatov et al. 2008) and that a wide array of basal phenotypes
measured in the α5−/− mouse are similar to WT (Salas et al. 2003, Jackson et al. 2010).
However, we still cannot discount that compensatory mechanisms with other nicotinic
subunits or non-nicotinic mechanisms may have potentially affected the results.
We were surprised to see that α5 gene deletion did not confer differences in
assays testing multiple aspects of drinking behavior.

Our expectations of seeing a

change in drinking behavior were bolstered by a previous study showing that
polymorphisms in the Chrna5-Chrna3-Chrnb4 gene cluster co-segregate with ethanol
preference in an F2 population produced from reciprocal crosses of ethanol-preferring
B6 and ethanol-avoiding D2 mouse strains (Symons et al. 2010). The study further
showed that these strains also exhibited differences in α5 mRNA levels, as the ethanolpreferring B6 strains contained significantly higher basal levels of α5 than D2 mice.
Given this evidence, we tested the effect of α5 gene deletion on various aspects of
drinking behavior in a battery of oral self-administration paradigms in mice. These
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included a standard two-bottle choice model, which assessed continuous access
drinking behavior within a range of ethanol concentrations, the intermittent access (IA)
model to assess escalation of drinking behavior induced by repeated episodes of
ethanol deprivation, and the Drinking-in-the-Dark (DID) model to assess acute binge
drinking behavior. However, there were no changes in drinking detected in α5−/− mice
in either of these paradigms. Our results with DID are in agreement with a previous
study showing no change in DID drinking behavior in α5−/− mice (Santos et al. 2012).
Nevertheless, we knew that ethanol preference is not reflected in the DID paradigm,
and therefore, thought it still reasonable to expect that changes in drinking behavior
might be still be detected in α5−/− mice when assessed for preference in the two-bottle
choice and IA paradigms. Our observations that α5 gene deletion did not alter drinking
behavior in mice may indicate that this may not necessarily be the case. Given the data
previously mentioned about the possible link between the role of α5* nAChRs in nicotine
and ethanol-responsive behaviors, we repeated our DID experiment to determine if α5
gene deletion would alter nicotine-modulated changes in drinking behavior.

As

expected, nicotine reduced ethanol intake in WT mice compared to saline-treated mice,
but unexpectedly, the data also revealed that both nicotine- and saline-treated
α5−/− mice drank less as well. This led us to speculate the possibility that these effects
are too subtle for a standard two-bottle choice procedure, IA, or DID alone to detect
under stress-free conditions.

Perhaps such effects are not discernible until the

presence of a stressor is introduced. Indeed, this was supported by the DID intake data
as multiple daily injections of saline in KO mice led to decreased drinking levels similar
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to WT mice that were treated with nicotine. In fact, we saw that α5−/− mice both, treated
with either saline or nicotine, drank similarly to WT nicotine-treated groups, suggesting
that the potential effect of nicotine in the α5−/− mice was masked by the physiological
changes induced by the stress of multiple daily injections. Literature suggests that
many procedures involved in animal research, including handling and injections, can
lead to various stress-related changes mediated by the HPA axis (Drude et al. 2011). It
may be possible that mild stress caused by these injections leads to HPA axis-mediated
changes in drinking behavior that occurs in mice with decreased α5* nAChR function.
This could suggest a link between α5* nAChRs and stress-induced drinking behavior.
The HPA axis is a key regulator in the release of hormones in response to stress and is
recognized for playing an important role in alcohol dependence (Madiera et al. 1999,
Heilig & Koob, 2007). Interestingly, compared to WT, α5−/− mice have been shown to
express higher basal levels of hypothalamic corticotropin releasing factor (CRF), an
HPA axis-mediated hormone that has generated great interest for its potential as a
therapeutic target for curbing stress- and anxiety-induced alcohol drinking (Heilig and
Koob, 2007, Gangitano et al. 2009). Despite this intriguing finding, the data are, so far,
only exploratory and there are caveats associated with our findings. In addition to the
previously discussed issue of compensation in KO mice, we did not measure changes
in stress-related hormones induced by these injections. Furthermore, we only obtained
data related to injection-induced stress, which is a mild form of stress (Márquez et al.
2002).

Much more work must be done to characterize the roles different types of

stressors have on the observed effects in these mice because many factors including
the type, frequency, and duration of stress among others can influence the end
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behaviors examined (Drude et al. 2011). For future studies, α5 WT and KO mice should
be assessed for drinking behavior following more severe stressors.

Tests such as

acoustic startle and restraint stress are classified as more severe since they display
longer and more profound effects on the HPA-axis (Drude et al. 2011, Kiank et al. 2008,
Depke et al. 2008). It will also be necessary to determine differences in basal levels of
stress hormones, such as CRF, and changes in the levels of these hormones in
response to severe stress in these mice.
Our results with α5 prompted further study of other an additional subtype, α4β2*,
with which the α5 subunit is commonly co-expressed.

As previously discussed, the

majority of our findings on disruption of α5* nAChR signaling on ethanol-responsive
behavior via gene deletion showed that this results in the modulation of acute behavioral
responses, and not ethanol drinking. This provides the possibility that the modulation of
ethanol’s acute effects is an α4β2α5* nAChR-mediated phenomenon. Furthermore, there
have been multiple studies showing the lack of involvement of α4β2* nAChRs on oral selfadministration of ethanol, but that do demonstrate the involvement of α3β4* nAChRs (Lé et
al. 2000, Hendrickson et al.2009, Kuzmin et al. 2009, Kamens et al.2010a, Chatterjee et al.
2011, Gallego et al. 2012). Our results, when combined with the literature seem to support
this idea. For example, the observation that drinking behavior in the intermittent access
paradigm did not differ between β2 WT and KO mice show that β2* nAChRs do not affect
chronic drinking behavior, even after repeated cycles of deprivation implemented in the IA
assay. As stated earlier, this is the outcome we were expecting and is in line with what the
literature suggests using various models of oral self-administration in rodents (Lé et al.
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2000, Larsson et al. 2004a,b; Hendrickson et al. 2009)..

It is also noteworthy that

additional studies using this same drinking model showed a lack of involvement of α6*, a
subtype which also often co-assembles with β2* (Yang et al. 2009, Kamens et al. 2012).
Taken together with our results, these data collectively demonstrate that antagonism of β2*
nAChRs do not have a discernible effect on ethanol consumption in a wide range of tests
of drinking behavior.
In further support of the theory that α4β2* nAChRs are involved in acute ethanolresponsive behaviors we used a panel of high affinity for α4β2* nicotinic ligands including
an antagonist (DHβE), a full agonist (nicotine), and two partial agonists (varenicline and
sazetidine-A), to show that manipulation of these receptors does modulate sensitivity to
acute ethanol administration in drug-naïve mice. Interestingly, these effects did not extend
to all the acute responses measured, as no change in ethanol-induced hypothermia,
locomotor depression, or latency to LORR were detected.

While our results with

hypothermia were novel and previously unexplored in literature, our locomotor results were
strengthened by the fact that β2* nAChR antagonism also had no effect on latency to
LORR, another measure of initial sensitivity to ethanol-induced sedation (Ponomarev &
Crabbe, 2002b). Interestingly, past pharmacological studies in mice and rats suggested a
role for α3β2/α3β4* nAChR subtypes in ethanol-induced locomotor stimulation (Larsson et
al. 2002, Kamens et al. 2008, 2009). It possible that α5 may be the additional subunit
contained in these subtypes that mediate the described effects. Unfortunately, our α5 (and
β2) KO mice exist on a C57BL/6 background that shows a minimal stimulant response to
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ethanol (Demarest et al.1999; Randall et al, 1975), and we were thus not able to test this
hypothesis.
The results that DHβE-pretreated and β2 KO mice displayed a significant difference
in LORR duration and not latency to LORR were very intriguing; even more so by the fact
that partial and full activation of α4β2* nAChRs by their respective agonists consistently
produced the opposite effect. It is generally accepted that level of response to acute
ethanol challenge may represent a combination of initial sensitivity to acute ethanol
exposure and acute functional tolerance directly following exposure (Ponomarev & Crabbe
2002b).

Because latency to LORR and LORR duration may correlate to these two

respective measures, the results may indicate that antagonism of β2* nAChR activity, as
shown by DHβE treatment and β2 gene deletion, enhance the rate of the neuronal
tolerance that develops minutes to hours after early ethanol exposure without necessarily
affecting the initial sensitivity to ethanol’s effects. This may explain why a difference in KO
mice was only seen in the LORR assay, and not the locomotor depression assay, since the
10 min time window measured in the latter may not have been long enough to observe β2’s
influence on this behavior. Our results with the partial and full agonists show that the
opposite may be true upon activation of α4β2* nAChRs. We are fairly confident that this is,
indeed, an α4β2*-mediated effect since, sazetidine-A, a compound with a many fold higher
selectivity for the α4β2* subtype than varenicline and nicotine (Xiao et al. 2006, Rezvani et
al. 2010), produced results consistent with the latter drugs. However, the nature of the
association of the α5 subunit with these receptors in mediating LORR effects remains a
mystery.

We were surprised to discover that the effects mediated by α4β2* nAChR
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activation in B6 mice matched those observed in KO mice with reduced α5* nAChR
function.

This was counter to our expectations that α5* nAChRs may mediate its

enhancement on the LORR phenotype through association with α4β2* nAChRs. It may be
possible, then, that α4β2* nAChRs have opposing effects on α5* nAChRs that do not
contain α4β2* (i.e. α3β2α5* or α3β4α5* nAChRs) in the case of this ethanol-induced
phenotype. Additionally, other nAChRs including α6 and α7 nAChR subunits have also
been implicated in the LORR. Deletion of α6* and α7 gene in mice display a significantly
higher LORR recovery time compared to WT animals, similar to the results we found with
deletion of α5 (Bowers et al., 2005; Kamens et al., 2012). Varenicline and nicotine, in
addition to their α4β2* actions, also act as full agonists at α7 and α6 (Mihilak et al. 2006,
Jackson et al. 2009). Thus, one would expect to see effects opposite of those observed in
the KO mice (i.e. reduction in LORR recovery time) if these phenomena were principally
mediated by α6* or α7 nAChRs. However, our results, taken within the context of the other
studies, demonstrates that activation of α4β2* nAChRs by these treatments may mask any
effects mediated by α6* and/or α7 nAChRs. Given this data, it is apparent that multiple
nAChR subtypes including, α4β2*, α5*, α6*, and α7, differentially influence response to the
hypnotic effects of ethanol, with α4β2* acting as the principal mediator of the observed
phenotype. Future studies should incorporate the use of α4−/− mice to shed further light on
the involvement of α4β2* nAChRs in this behavior. Furthermore, it will be useful to repeat
the aforementioned tests over a range of multiple ethanol doses to determine the extent of
the effects of nAChR manipulation on ethanol’s hypnotic effects. Regardless, the results
we have obtained so far underscore the underlying complexities that individual genetic
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makeup has on determining the nAChR contribution to initial sensitivity to early ethanol
exposure
Our results also showed that both DHβE-pretreated and β2* KO mice demonstrated
an enhanced response to ethanol’s effect on reducing anxiety-like behavior in these
subjects during the EPM test. These data may suggest that functional disruption of β2*
nAChRs affects some aspects of the anxiolytic-like effects induced by acute ethanol
administration in mice.

The experiment showing the attenuated effect of DHβE

pretreatment in β2 KO mice seems to support this idea. We also found that α5 gene
deletion and nicotine-pretreatment also had similar effects on open arm time in B6 mice as
the previously mentioned test groups.

Our results with varenicline and sazetidine-A,

unfortunately, were inconclusive due their locomotor altering effects.

While we were

careful to choose pharmacologically-relevant doses of varenicline and sazetidine-A that did
not affect locomotor activity by themselves (Kamens et al. 2010, Rezvani et al. 2010), it
seems their combination with ethanol caused a significant reduction in crossovers in the
test, which likely affected the time spent in the open arms. However, except for those
mentioned groups, none of the behavior observed in any other experiment was due to
changes in animal locomotor activity since there was no difference in the number of
crossovers across all treatment groups. The fact that α5−/− mice displayed similar behavior
in the same paradigm as β2 KO and DHβE-pretreated mice, supports the idea that this may
be an α4β2α5*-mediated effect.

It is possible that α4β2α5* nAChRs mediate an

endogenous pathway(s) that negatively modulate ethanol’s effects on this behavioral trait.
Interestingly, β2 nAChR subunits are expressed in brain regions including the amygdala,
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the hippocampus, and limbic regions, which are known to regulate anxiety behaviors
(Silveira et al. 1993, Walf et al. 2007, Gotti et al. 2007).
As for the results with nicotine pre-treatment, while is logical to assume that
activation of α4β2α5* nAChRs would have the opposite effect on that of the KO, which we
did not observe, it is possible that nicotine was able to mimic the effects of β2* and α5*
nAChR antagonism through desensitization of α4β2α5* receptors. The incorporation of the
α5 subunit has a significant influence on the desensitization properties of the subtype with
which it is co-expressed (Gerzanich et al. 1998). For α4β2* nAChRs, particularly, coexpression with α5 can increase receptor desensitization rates, and, furthermore, can
affect agonist efficacy and sensitivity of these receptors (Mao et al 2008, Kuryatov et al.
2008). As mentioned previously, desensitization occurs when agonist binding eventually
causes the receptor to transition into an agonist bound, but non-conducting state
(Gerzanich et al. 1998). The (α4β2)2α5 subtype is an important player in neurotransmitter
release in the VTA, and is particularly sensitive to activation by nicotine (McClure-Begley et
al. 2009, Kuryatov et al. 2011). Interestingly it theorized that a reduction of α5* nAChR
function by an amino acid variant in the α5 gene results in a deficiency in nicotine-induced
α5* nAChR signaling that may lead to enhanced nicotine intake to achieve its desired
effects (Bierut et al. 2009, Kuryatov et al. 2011).
Perhaps, the opposite is true with alcohol in which an enhanced response to its
anxiolytic properties (as well as sedative effects) reduces the need for further intake. This
could provide a possible explanation for the contrasting results discovered in the GWA
studies regarding the association of the functional polymorphism with nicotine and alcohol
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dependence risk. However, such speculations must be made with caution. When used
appropriately, the EPM test can be a very valuable tool in drug testing and our results
suggest that one aspect of anxiety and emotional behavior is modulated by alcoholnicotinic interaction. Nevertheless, we realize it is likely that different tests for anxiety-like
behaviors will measure somewhat different forms of emotional behavior and anxiety, which
may be mediated by distinct neural circuits and genes. Investigating additional models that
test different aspects of anxiety in order to further understand the nature of the role of this
nAChR subtype in ethanol’s anxiolytic effects are needed. Some suggested models for
future studies include light dark box, marble burying, open-field, and startle response,
which could each be used to assess the effect of nAChR manipulation on distinct aspects
of ethanol-induced anxiolysis. Each of these are reliable models of analyzing anxiety-like
behavior in rodents and are distinctly utilized for screening anxiolytic agents like ethanol
(Hart et al. 2010).

The implication of such tests could be important especially when

considering that anxiety behavior is thought to serve as a motivating factor for sustained
alcohol consumption in humans that may increase risk for excessive drinking in the future
(Spanagel et al. 1995, Zimmerman et al. 2003).
We are confident that the effects we observed in all of our acute studies in the KO
mice were not due to changes in ethanol metabolism between the α5 and β2 KO genotypes
and their WT counterparts. Our data showed no difference in BEC levels over 2-hr time
course between α5−/− and α5+/+ mice treated with a high dose of ethanol. Additionally,
while ethanol pharmacokinetics were not directly studied in the β2 KO and WT mice, we
believe that differences in ethanol metabolism between the two genotypes do not play an
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important role in the decrease in the LORR phenotype for a couple reasons. A similar
decrease in the LORR response was also seen with the β2* antagonist, DHβE. Also, no
difference in hypothermia and hypomotility induced by ethanol was found between β2 KO
and WT mice. Several subunits in addition to α5, including α4, α6, and β3 are often coexpressed with β2 subunits generating multiple β2-containing nAChR subtypes (Gotti et al.
2007). While our studies did not address the composition of β2* subtypes involved in
ethanol’s effects, our data likely suggest the involvement of α4β2* subtypes due the
similarity of the results displayed between mice pretreated with DHβE, an antagonist with
high affinity for α4β2* nAChRs, and β2−/− mice. A limitation of our study is the chance that
the effects observed in β2−/− mice were due to compensatory or developmental changes
that occur with the deletion of their respective genes.

While the expression of many

nAChR subunits, namely α4, α5, β4, and β3, are not altered by removal of the β2 gene
(Picciotto et al.1995, 1998), compensatory mechanisms with other nicotinic subunits or
non-nicotinic mechanisms are still unknown. Importantly, our results with β2−/− mice were
complemented with those seen with DHβE, a selective β2* nAChR antagonist. We could
not make this same confirmation for the results in α5−/− mice due to the lack of an available
antagonist selective for this subtype. However, α5−/− mice have been repeatedly assessed
for many basal phenotypes and do not appear to differ remarkably from WT mice in these
behavioral measures (Salas et al. 2003, Jackson et al. 2010).
As with our results regarding α5, our assessment of β2* nAChRs in ethanolresponsive behaviors seem to complement the human genetics studies providing
support for the role of Chrnb2 in alcohol behaviors as well. Consistent with what we
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observed in animal models, human genetic association studies have implicated Chrnb2
in alcohol behaviors because an association between polymorphisms in the Chrnb2
gene and initial subjective response to early alcohol exposure was found (Ehringer et al.
2007).

Therefore, nicotinic receptors, along with being key components in nicotine

dependence, may also present viable candidates in the discovery of molecular
underpinnings of behaviors related to alcohol dependence. Our results support the
hypothesis that behavioral responses to alcohol and nicotine are likely to be
differentially modulated by specific nicotinic subunits.

We hope these studies will

provide important information for the future development of pharmacotherapies in the
ongoing search for a treatment for alcohol dependence, and potentially nicotine
dependence simultaneously.
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